MF Researcher Database

Researcher Database

Advance

Tsurutani Junji

■FacultyAdvanced Cancer Translational Research Institute
■PositionExtraordinary Professor
Last Updated :2025/04/01

Researcher

基本情報

Profile and Settings

  • 顔写真

  • 氏名

    Tsurutani Junji

  • eメール

    tsurutajmed.showa-u.ac.jp

Identifiers

  • ORCID ID

    0000-0002-6260-6943

Affiliation

  • Advanced Cancer Translational Research Institute, Extraordinary Professor

Location

  • Hatanodai Campus

Degree

  • Doctor of Medical Science, Nagasaki University, Mar. 2007

Research Keywords

  • Clinical Oncology, Medical Oncology, Breast Cancer, Clinical Trial, Drug Development, Molecular Target Medicine, Antibody Drug Conjugate, Cell Signaling

Teaching Subjects

  • Aug. 2018

Committee Memberships

  • JSMO director, Feb. 2024
  • JSMO councilor, Apr. 2011
  • JBCS councilor, Apr. 2011
  • DESTINY-Breast04 steering committee, Jan. 2019
  • TROPION-Breast01 steering committee, Jan. 2021
  • HER2-CLIMB05 steering committee, Jan. 2022
  • Monarh study translational research, steering committee, Oct. 2023
  • Dato-DXd Global Commercial Breast Cancer Steering Committee, Apr. 2023
  • Safety advisor committee for Enhertu, Apr. 2019

Awards

  • Showa University, Kamijo Award, Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors., Jun. 2021, Japan
  • JBCS, Best of Breast Cancer Award, Oct. 2020, Japan
  • JSCO, research award, cfDNA analysis in HER2 positve breast cancer, Apr. 2016, Japan
  • Kinki University, Research Award, Phase I study of nab-paclitaxel and S-1 in ABC, Oct. 2015, Japan
  • Lynn Sage Breast Cancer Foundation, Travel Award, Lynn Sage Cancer Symposium (Chicago), 2010, Japan
  • West Japan Oncology Group, WJOG4409 GTR, Apr. 2009, Japan

Achievements

Published Papers

  • A randomized, double-blind, placebo-controlled phase II study of olanzapine-based prophylactic antiemetic therapy for delayed and persistent nausea and vomiting in patients with HER2-positive or HER2-low breast cancer treated with trastuzumab deruxtecan: ERICA study (WJOG14320B), Hitomi Sakai, Junji Tsurutani, et al., Annals of Oncology, Sep. 2024, Peer-reviewed, DOI:10.1016/j.annonc.2024.09.001
  • Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2- and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study., Bardia Aditya;Krop Ian E;Kogawa Takahiro;Juric Dejan;Tolcher Anthony W;Hamilton Erika P;Mukohara Toru;Lisberg Aaron;Shimizu Toshio;Spira Alexander I;Tsurutani Junji;Damodaran Senthil;Papadopoulos Kyriakos P;Greenberg Jonathan;Kobayashi Fumiaki;Zebger-Gong Hong;Wong Rie;Kawasaki Yui;Nakamura Tadakatsu;Meric-Bernstam Funda, Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 42(19), Apr. 2024, Peer-reviewed
  • Risk factors for recurrence in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative early breast cancer in Japan: a systematic literature review and meta-analysis., Miyazaki Naoki;Iwasaki Toshiki;Sakai Hitomi;Watanuki Rurina;Tanizawa Yoshinori;Cai Zhihong;Kawaguchi Tsutomu;Tsurutani Junji;Nagashima Kengo, Current medical research and opinion, 40(5), Apr. 2024, Peer-reviewed
  • Trastuzumab deruxtecan for human epidermal growth factor receptor 2-low advanced or metastatic breast cancer: recommendations from the Japanese Breast Cancer Society Clinical Practice Guidelines., Hattori Masaya;Honma Naoko;Nagai Shigenori;Narui Kazutaka;Shigechi Tomoko;Ozaki Yukinori;Yoshida Masayuki;Sakatani Takashi;Sasaki Eiichi;Tanabe Yuko;Tsurutani Junji;Takano Toshimi;Saji Shigehira;Masuda Shinobu;Horii Rie;Tsuda Hitoshi;Yamaguchi Rin;Toyama Tatsuya;Yamauchi Chikako;Toi Masakazu;Yamamoto Yutaka, Breast cancer (Tokyo, Japan), Mar. 2024
  • Trastuzumab deruxtecan in previously treated patients with HER2-positive metastatic breast cancer: updated survival results from a phase II trial (DESTINY-Breast01), Saura C, Modi S, Krop I, Park YH, Kim SB, Tamura K, Iwata H, Tsurutani J, Sohn J, Mathias E, Liu Y, Cathcart J, Singh J, Yamashita T., Annals of Oncology, 35(3):302 - 307, Mar. 2024, Peer-reviewed
  • Trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2-expressing salivary gland carcinoma: a pooled analysis of two phase I studies., Takahashi Shunji;Bando Hideaki;Kinoshita Ichiro;Modi Shanu;Tsurutani Junji;Bang Yung-Jue;Sato Yuta;Nakatani Shunsuke;Lee Caleb;Sugihara Masahiro;Okuda Yasuyuki;Iwata Hiroji, Japanese journal of clinical oncology, Jan. 2024, Peer-reviewed
  • 抗体薬物複合体に対する耐性と克服(T-DM1とT-DXdなど), 鶴谷 純司;酒井 瞳, 腫瘍内科, 32(5):575 - 579, Nov. 2023, Peer-reviewed
  • Analytical and clinical validation of PATHWAY Anti-HER-2/neu (4B5) antibody to assess HER2-low status for trastuzumab deruxtecan treatment in breast cancer., Garrido Charo;Manoogian Melissa;Ghambire Dhiraj;Lucas Shawn;Karnoub Maha;Olson Matthew T;Hicks David G;Tozbikian Gary;Prat Aleix;Ueno Naoto T;Modi Shanu;Feng Wenqin;Pugh Judith;Hsu Ching;Tsurutani Junji;Cameron David;Harbeck Nadia;Fang Qijun;Khambata-Ford Shirin;Liu Xuemin;Inge Landon J;Vitazka Patrik, Virchows Archiv : an international journal of pathology, Oct. 2023, Peer-reviewed
  • Treatment with trastuzumab deruxtecan in patients with HER2-positive breast cancer and brain metastases and/or leptomeningeal disease (ROSET-BM)., Niikura Naoki;Yamanaka Takashi;Nomura Hironori;Shiraishi Kazuhiro;Kusama Hiroki;Yamamoto Mitsugu;Matsuura Kazuo;Inoue Kenichi;Takahara Sachiko;Kita Shosuke;Yamaguchi Miki;Aruga Tomoyuki;Shibata Nobuhiro;Shimomura Akihiko;Ozaki Yuri;Sakai Shuji;Kiga Yoko;Izutani Tadahiro;Shiosakai Kazuhito;Tsurutani Junji, NPJ breast cancer, 9(1), Oct. 2023, Peer-reviewed
  • Efficacy of probiotics and trimebutine maleate for abemaciclib-induced diarrhea: A randomized, open-label phase II trial (MERMAID, WJOG11318B)., Masuda Hiroko;Tanabe Yuko;Sakai Hitomi;Matsumoto Koji;Shimomura Akihiko;Doi Mihoko;Miyoshi Yasuo;Takahashi Masato;Sagara Yasuaki;Tokunaga Shinya;Iwasa Tsutomu;Niikura Naoki;Yoshimura Kenichi;Takano Toshimi;Tsurutani Junji, Breast (Edinburgh, Scotland), 71, Jul. 2023, Peer-reviewed
  • Novel single nucleotide polymorphism biomarkers to predict opioid effects for cancer pain., Fujita Yoshihiko;Matsuoka Hiromichi;Chiba Yasutaka;Tsurutani Junji;Yoshida Takeshi;Sakai Kiyohiro;Nakura Miki;Sakamoto Ryo;Makimura Chihiro;Ohtake Yoichi;Tanaka Kaoru;Hayashi Hidetoshi;Takeda Masayuki;Okuno Tatsuya;Takegawa Naoki;Haratani Koji;Takahama Takayuki;Tanizaki Junko;Koyama Atsuko;Nishio Kazuto;Nakagawa Kazuhiko, Oncology letters, 26(2), Jul. 2023, Peer-reviewed
  • TROPION-Breast01: Datopotamab deruxtecan vs chemotherapy in pre-treated inoperable or metastatic HR+/HER2- breast cancer., Bardia Aditya;Jhaveri Komal;Kalinsky Kevin;Pernas Sonia;Tsurutani Junji;Xu Binghe;Hamilton Erika;Im Seock-Ah;Nowecki Zbigniew;Sohn Joohyuk;Laurentiis Michelino De;Jañez Noelia Martínez;Adamo Barbara;Lee Keun Seok;Jung Kyung Hae;Rubovszky Gábor;Tseng Ling-Ming;Lu Yen-Shen;Yuan Yuan;Maxwell Micah J;Haddad Vincent;Khan Sabrina S;Rugo Hope S;Pistilli Barbara, Future oncology (London, England), Jun. 2023, Peer-reviewed
  • Real-world treatment patterns and outcomes of abemaciclib for the treatment of HR + , HER2- metastatic breast cancer patients in Japan., Nozawa K;Terada M;Onishi M;Ozaki Y;Takano T;Fakhouri W;Novick D;Haro J M;Faris L H;Kawaguchi T;Tanizawa Y;Tsurutani Junji, Breast cancer (Tokyo, Japan), 30(4), May 2023, Peer-reviewed
  • Multicentre, randomised, double-blind, placebo-controlled phase II study of prophylactic olanzapine for patients with metastatic breast cancer receiving T-DXd treatment: protocol for the ERICA study (WJOG14320B)., Sakai Hitomi;Tsurutani Junji;Ozaki Yukinori;Ishiguro Hiroshi;Nozawa Kazuki;Watanabe Kenichi;Maeda Shigeto;Yokoe Takamichi;Imamura Chiyo K;Matsumoto Koji;Iwasa Tsutomu;Chiba Yasutaka;Takiguchi Daisuke;Takano Toshimi, BMJ open, 13(4), Apr. 2023, Peer-reviewed
  • Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial., Sara A Hurvitz; Roberto Hegg; Wei-Pang Chung; Seock-Ah Im; William Jacot; Vinod Ganju; Joanne Wing Yan Chiu; Binghe Xu; Erika Hamilton; Srinivasan Madhusudan; Hiroji Iwata; Sevilay Altintas; Jan-Willem Henning; Giuseppe Curigliano; José Manuel Perez-Garcia; Sung-Bae Kim; Vanessa Petry; Chiun-Sheng Huang; Wei Li; Jean-Sebastien Frenel; Silvia Antolin; Winnie Yeo; Giampaolo Bianchini; Sherene Loi; Junji Tsurutani; Anton Egorov; Yali Liu; Jillian Cathcart; Shahid Ashfaque; Javier Cortés, Lancet (London, England), 401(10371):105 - 117, Jan. 2023, Peer-reviewed
  • Efficacy and exploratory biomarker analysis of entinostat plus exemestane in advanced or recurrent breast cancer: phase II randomized controlled trial., Iwata Hiroji;Nakamura Rikiya;Masuda Norikazu;Yamashita Toshinari;Yamamoto Yutaka;Kobayashi Kokoro;Tsurutani Junji;Iwasa Tsutomu;Yonemori Kan;Tamura Kenji;Aruga Tomoyuki;Tokunaga Eriko;Kaneko Koji;Lee Min-Jung;Yuno Akira;Kawabata Azusa;Seike Toshihiro;Kaneda Ayumi;Nishimura Yozo;Trepel Jane B;Saji Shigehira, Japanese journal of clinical oncology, 53(1), 2023, Peer-reviewed
  • Efficacy, safety, and biomarker analysis of nivolumab in combination with abemaciclib plus endocrine therapy in patients with HR-positive HER2-negative metastatic breast cancer: a phase II study (WJOG11418B NEWFLAME trial)., Masuda Jun;Sakai Hitomi;Tsurutani Junji;Tanabe Yuko;Masuda Norikazu;Iwasa Tsutomu;Takahashi Masato;Futamura Manabu;Matsumoto Koji;Aogi Kenjiro;Iwata Hiroji;Hosonaga Mari;Mukohara Toru;Yoshimura Kiyoshi;Imamura Chiyo K;Miura Sakiko;Yamochi Toshiko;Kawabata Hidetaka;Yasojima Hiroyuki;Tomioka Nobumoto;Yoshimura Kenichi;Takano Toshimi, Journal for immunotherapy of cancer, 11(9), 2023, Peer-reviewed
  • Morphine Versus Oxycodone for Cancer Pain Using a Catechol-O-methyltransferase Genotype Biomarker: A Multicenter, Randomized, Open-Label, Phase III Clinical Trial (RELIEF Study)., Matsuoka Hiromichi;Tsurutani Junji;Chiba Yasutaka;Fujita Yoshihiko;Sakai Kiyohiro;Yoshida Takeshi;Nakura Miki;Sakamoto Ryo;Makimura Chihiro;Ohtake Yoichi;Tanaka Kaoru;Hayashi Hidetoshi;Takeda Masayuki;Okuno Tatsuya;Takegawa Naoki;Haratani Koji;Koyama Atsuko;Nishio Kazuto;Nakagawa Kazuhiko, The oncologist, 28(3), 2023, Peer-reviewed
  • Mechanisms of EGFR-TKI-Induced Apoptosis and Strategies Targeting Apoptosis in EGFR-Mutated Non-Small Cell Lung Cancer., Nishihara Shigetoshi;Yamaoka Toshimitsu;Ishikawa Fumihiro;Higuchi Kensuke;Hasebe Yuki;Manabe Ryo;Kishino Yasunari;Kusumoto Sojiro;Ando Koichi;Kuroda Yusuke;Ohmori Tohru;Sagara Hironori;Yoshida Hitoshi;Tsurutani Junji, Genes, 13(12), Nov. 2022, Peer-reviewed
  • Data of programmed death-ligand 1 expression and VEGF: Nivolumab, bevacizumab and paclitaxel For HER2-negative metastatic breast cancer., Ozaki Yukinori;Tsurutani Junji;Mukohara Toru;Iwasa Tsutomu;Takahashi Masato;Tanabe Yuko;Kawabata Hidetaka;Masuda Norikazu;Futamura Manabu;Minami Hironobu;Matsumoto Koji;Yoshimura Kenichi;Kitano Shigehisa;Takano Toshimi, Data in brief, 45, Sep. 2022, Peer-reviewed
  • Diverse Mechanisms of Resistance against Osimertinib, a Third-Generation EGFR-TKI, in Lung Adenocarcinoma Cells with an EGFR-Activating Mutation., Nishihara Shigetoshi;Yamaoka Toshimitsu;Ishikawa Fumihiro;Ohmori Tohru;Ando Koichi;Kusumoto Sojiro;Kishino Yasunari;Manabe Ryo;Hasebe Yuki;Sagara Hironori;Yoshida Hitoshi;Tsurutani Junji, Cells, 11(14), Jul. 2022, Peer-reviewed
  • Safety and efficacy of nivolumab plus bevacizumab, paclitaxel for HER2-negative metastatic breast cancer: Primary results and biomarker data from a phase 2 trial (WJOG9917B)., Ozaki Yukinori;Tsurutani Junji;Mukohara Toru;Iwasa Tsutomu;Takahashi Masato;Tanabe Yuko;Kawabata Hidetaka;Masuda Norikazu;Futamura Manabu;Minami Hironobu;Matsumoto Koji;Yoshimura Kenichi;Kitano Shigehisa;Takano Toshimi, European journal of cancer (Oxford, England : 1990), 171, Jun. 2022, Peer-reviewed
  • Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer., Modi Shanu;Jacot William;Yamashita Toshinari;Sohn Joohyuk;Vidal Maria;Tokunaga Eriko;Tsurutani Junji;Ueno Naoto T;Prat Aleix;Chae Yee Soo;Lee Keun Seok;Niikura Naoki;Park Yeon Hee;Xu Binghe;Wang Xiaojia;Gil-Gil Miguel;Li Wei;Pierga Jean-Yves;Im Seock-Ah;Moore Halle C F;Rugo Hope S;Yerushalmi Rinat;Zagouri Flora;Gombos Andrea;Kim Sung-Bae;Liu Qiang;Luo Ting;Saura Cristina;Schmid Peter;Sun Tao;Gambhire Dhiraj;Yung Lotus;Wang Yibin;Singh Jasmeet;Vitazka Patrik;Meinhardt Gerold;Harbeck Nadia;Cameron David A; , The New England journal of medicine, 387(1), Jun. 2022, Peer-reviewed
  • Evaluation of a novel medical device for pegfilgrastim administration., Aruga Tomoyuki;Doihara Hiroyoshi;Yanagita Yasuhiro;Ishida Takanori;Yamashita Toshinari;Uehara Kanou;Taira Tetsuhiko;Tsurutani Junji;Takeshita Takashi;Tsuyuki Shigeru;Kaneko Koji;Ohtake Tohru;Yamaguchi Yusuke;Hara Yui;Saji Shigehira, Cancer science, 113(5), Mar. 2022, Peer-reviewed
  • Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)-related interstitial lung disease/pneumonitis-Focus on proactive monitoring, diagnosis, and management., Swain Sandra M;Nishino Mizuki;Lancaster Lisa H;Li Bob T;Nicholson Andrew G;Bartholmai Brian J;Naidoo Jarushka;Schumacher-Wulf Eva;Shitara Kohei;Tsurutani Junji;Conte Pierfranco;Kato Terufumi;Andre Fabrice;Powell Charles A, Cancer treatment reviews, 106, Mar. 2022, Peer-reviewed
  • A phase 3 safety study of fosnetupitant as an antiemetic in patients receiving anthracycline and cyclophosphamide: CONSOLE-BC., Matsuura Kazuo;Tsurutani Junji;Inoue Kenichi;Tanabe Yuko;Taira Tetsuhiko;Kubota Kaoru;Tamura Tomohide;Saeki Toshiaki, Cancer, 128(8), Jan. 2022, Peer-reviewed
  • Association of Genetic Polymorphism with Taxane-induced Peripheral Neuropathy: Sub-analysis of a Randomized Phase II Study to Determine the Optimal Dose of 3-week Cycle Nab-Paclitaxel in Metastatic Breast Cancer Patients., Abe Yuko;Taira Naruto;Kashiwabara Kosuke;Tsurutani Junji;Kitada Masahiro;Takahashi Masato;Kato Hiroaki;Kikawa Yuichiro;Sakata Eiko;Naito Yoichi;Hasegawa Yoshie;Saito Tsuyoshi;Iwasa Tsutomu;Takashima Tsutomu;Aihara Tomohiko;Mukai Hirofumi;Hara Fumikata;Shien Tadahiko;Doihara Hiroyoshi;Toyooka Shinichi, Acta medica Okayama, 76(6), 2022, Peer-reviewed
  • Correction to: Quality of life in a randomized phase II study to determine the optimal dose of 3-week cycle nab-paclitaxel in patients with metastatic breast cancer., Taira Naruto;Kashiwabara Kosuke;Tsurutani Junji;Kitada Masahiro;Takahashi Masato;Kato Hiroaki;Kikawa Yuichiro;Sakata Eiko;Naito Yoichi;Hasegawa Yoshie;Saito Tsuyoshi;Iwasa Tsutomu;Takashima Tsutomu;Aihara Tomohiko;Mukai Hirofumi;Hara Fumikata, Breast cancer (Tokyo, Japan), 29(1), 2022, Peer-reviewed
  • Increased Plasma Soluble PD-1 Concentration Correlates with Disease Progression in Patients with Cancer Treated with Anti-PD-1 Antibodies., Ohkuma Ryotaro;Ieguchi Katsuaki;Watanabe Makoto;Takayanagi Daisuke;Goshima Tsubasa;Onoue Rie;Hamada Kazuyuki;Kubota Yutaro;Horiike Atsushi;Ishiguro Tomoyuki;Hirasawa Yuya;Ariizumi Hirotsugu;Tsurutani Junji;Yoshimura Kiyoshi;Tsuji Mayumi;Kiuchi Yuji;Kobayashi Shinichi;Tsunoda Takuya;Wada Satoshi, Biomedicines, 9(12), Dec. 2021, Peer-reviewed
  • Quality of life in a randomized phase II study to determine the optimal dose of 3-week cycle nab-paclitaxel in patients with metastatic breast cancer., Taira Naruto;Kashiwabara Kosuke;Tsurutani Junji;Kitada Masahiro;Takahashi Masato;Kato Hiroaki;Kikawa Yuichiro;Sakata Eiko;Naito Yoichi;Hasegawa Yoshie;Saito Tsuyoshi;Iwasa Tsutomu;Takashima Tsutomu;Aihara Tomohiko;Mukai Hirofumi;Hara Fumikata, Breast cancer (Tokyo, Japan), 29(1):131 - 143, Sep. 2021, Peer-reviewed
  • Capecitabine in Combination with Endocrine Therapy as Maintenance Therapy after Bevacizumab Plus Paclitaxel Induction Therapy for Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: KBCSG-TR1214., Norikazu Masuda; Tetsuhiro Yoshinami; Masahiko Ikeda; Makiko Mizutani; Miki Yamaguchi; Yoshifumi Komoike; Tsutomu Takashima; Katsuhide Yoshidome; Junji Tsurutani; Mitsuhiko Iwamoto; Fumie Fujisawa; Hiroyuki Yasojima; Jun Yamamura; Hirotaka Morishima; Fuminori Aki; Tomomi Yamada; Satoshi Morita; Takahiro Nakayama, Cancers, 13(17), Aug. 2021, Peer-reviewed
  • Correction to: The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2018 edition., Tatsunori Shimoi; Shigenori E Nagai; Tetsuhiro Yoshinami; Masato Takahashi; Hitoshi Arioka; Mikiya Ishihara; Yuichiro Kikawa; Kei Koizumi; Naoto Kondo; Yasuaki Sagara; Masahiro Takada; Toshimi Takano; Junji Tsurutani; Yoichi Naito; Rikiya Nakamura; Masaya Hattori; Fimikata Hara; Naoki Hayashi; Toshiro Mizuno; Minoru Miyashita; Nami Yamashita; Takashi Yamanaka; Shigehira Saji; Hiroji Iwata; Tatsuya Toyama, Breast cancer (Tokyo, Japan), 28(4):985 - 986, Jul. 2021
  • Indices of peripheral leukocytes predict longer overall survival in breast cancer patients on eribulin in Japan., Masato Takahashi; Kenichi Inoue; Hirofumi Mukai; Takashi Yamanaka; Chiyomi Egawa; Yasuo Miyoshi; Yukinori Sakata; Kenzo Muramoto; Hiroki Ikezawa; Toshiyuki Matsuoka; Junji Tsurutani, Breast cancer (Tokyo, Japan), 28(4):945 - 955, Jul. 2021, Peer-reviewed
  • Rare Nivolumab-associated Super Hyper Progressive Disease in Patients With Advanced Gastric Cancer, Yutaro Kubota; Kiyoshi Yoshimura; Kazuyuki Hamada; Yuya Hirasawa; Midori Shida; Makoto Taniguchi; Hiroto Matsui; Hirotsugu Ariizumi; Tomoyuki Ishiguro; Norihiro Suzuki; Ryotaro Ohkuma; Takehiko Sambe; Hiroo Ishida; Atsushi Horiike; Satoshi Wada; Junji Tsurutani; Sanju Iwamoto; Naoki Uchida; Yuji Kiuchi; Shinichi Kobayashi; Takuya Tsunoda, IN VIVO, 35(3):1865 - 1875, May 2021
  • A Correlation Analysis Between Metabolism-related Genes and Treatment Response to S-1 as First-line Chemotherapy for Metastatic Breast Cancer: The SELECT BC-EURECA Study., Tsutomu Takashima; Fumikata Hara; Takayuki Iwamoto; Yukari Uemura; Shozo Ohsumi; Daisuke Yotsumoto; Yasuo Hozumi; Takanori Watanabe; Tsuyoshi Saito; Ken-Ichi Watanabe; Junji Tsurutani; Tatsuya Toyama; Hiromitsu Akabane; Reiki Nishimura; Naruto Taira; Yasuo Ohashi; Hirofumi Mukai, Clinical breast cancer, 21(5):450 - 457, Feb. 2021, Peer-reviewed
  • Novel Anti-FOLR1 Antibody-Drug Conjugate MORAb-202 in Breast Cancer and Non-Small Cell Lung Cancer Cells., Matsunaga Yuki;Yamaoka Toshimitsu;Ohba Motoi;Miura Sakiko;Masuda Hiroko;Sangai Takafumi;Takimoto Masafumi;Nakamura Seigo;Tsurutani Junji, Antibodies (Basel, Switzerland), 10(1):6, Feb. 2021, Peer-reviewed, DOI:10.3390/antib10010006
  • Randomized phase II study to determine the optimal dose of 3-week cycle nab-paclitaxel in patients with metastatic breast cancer., Junji Tsurutani; Fumikata Hara; Masahiro Kitada; Masato Takahashi; Yuichiro Kikawa; Hiroaki Kato; Eiko Sakata; Yoichi Naito; Yoshie Hasegawa; Tsuyoshi Saito; Tsutomu Iwasa; Naruto Taira; Tsutomu Takashima; Kosuke Kashiwabara; Tomohiko Aihara; Hirofumi Mukai, Breast (Edinburgh, Scotland), 55(1):63 - 68, Feb. 2021, Peer-reviewed
  • Characteristics of interstitial lung disease in patients from post-marketing data on metastatic breast cancer patients who received abemaciclib in Japan., Chen Yucherng;Noma Satoshi;Taguchi Yoshio;Takahashi Masashi;Tsurutani Junji;Mori Shiho;Sakaguchi Sachi;Asou Hiroya;Tomii Keisuke, Breast cancer (Tokyo, Japan), 28(3), Jan. 2021, Peer-reviewed
  • High levels of human epididymis protein 4 mRNA and protein expression are associated with chemoresistance and a poor prognosis in pancreatic cancer., Ryotaro Ohkuma; Erica Yada; Shumpei Ishikawa; Daisuke Komura; Yutaro Kubota; Kazuyuki Hamada; Atsushi Horiike; Tomoyuki Ishiguro; Yuya Hirasawa; Hirotsugu Ariizumi; Midori Shida; Makoto Watanabe; Rie Onoue; Kiyohiro Ando; Junji Tsurutani; Kiyoshi Yoshimura; Tetsuro Sasada; Takeshi Aoki; Masahiko Murakami; Tomoko Norose; Nobuyuki Ohike; Masafumi Takimoto; Shinichi Kobayashi; Takuya Tsunoda; Satoshi Wada, International journal of oncology, 58(1):57 - 69, Jan. 2021, Peer-reviewed
  • Antibiotic Usage Reduced Overall Survival by over 70% in Non-small Cell Lung Cancer Patients on Anti-PD-1 Immunotherapy., Hamada Kazuyuki;Yoshimura Kiyoshi;Hirasawa Yuya;Hosonuma Masahiro;Murayama Masakazu;Narikawa Yoichiro;Ariizumi Hirotsugu;Ohkuma Ryotaro;Shida Midori;Kubota Yutaro;Matsukuma Satoshi;Ishiguro Tomoyuki;Sambe Takehiko;Horiike Atsushi;Kuramasu Atsuo;Wada Satoshi;Tsurutani Junji;Inoue Eisuke;Uchida Naoki;Kiuchi Yuji;Kobayashi Shinichi;Hoffman Robert M;Tsunoda Takuya, Anticancer research, 41(10), 2021, Peer-reviewed
  • The Prognostic Impact of Eosinophils and the Eosinophil-to-Lymphocyte Ratio on Survival Outcomes in Stage II Resectable Pancreatic Cancer., Ohkuma Ryotaro;Kubota Yutaro;Horiike Atsushi;Ishiguro Tomoyuki;Hirasawa Yuya;Ariizumi Hirotsugu;Watanabe Makoto;Onoue Rie;Ando Kiyohiro;Tsurutani Junji;Yoshimura Kiyoshi;Aoki Takeshi;Murakami Masahiko;Kobayashi Shinichi;Tsunoda Takuya;Wada Satoshi, Pancreas, 50(2), 2021, Peer-reviewed
  • BRCAness as a prognostic indicator in patients with early breast cancer., Liu Lei;Matsunaga Yuki;Tsurutani Junji;Akashi-Tanaka Sadako;Masuda Hiroko;Ide Yoshimi;Hashimoto Rikako;Inuzuka Mayuko;Watanabe Chie;Taruno Kanae;Sawada Terumasa;Okuyama Hiromi;Ata Arisa;Kuwayama Takashi;Nakayama Sayuka;Tonouchi Yumi;Nakamura Seigo, Scientific reports, 10(1):21173, Dec. 2020, Peer-reviewed
  • High expression levels of polymeric immunoglobulin receptor are correlated with chemoresistance and poor prognosis in pancreatic cancer, Ryotaro Ohkuma; Erica Yada; Shumpei Ishikawa; Daisuke Komura; Yutaro Kubota; Kazuyuki Hamada; Atsushi Horiike; Tomoyuki Ishiguro; Yuya Hirasawa; Hirotsugu Ariizumi; Midori Shida; Makoto Watanabe; Rie Onoue; Kiyohiro Ando; Junji Tsurutani; Kiyoshi Yoshimura; Tetsuro Sasada; Takeshi Aoki; Masahiko Murakami; Tomoko Norose; Nobuyuki Ohike; Masafumi Takimoto; Shinichi Kobayashi; Takuya Tsunoda; Satoshi Wada, Oncology Reports, 44(1):252 - 262, Jul. 2020, Peer-reviewed
  • Reply to T.J.A. Dekker., Shanu Modi; Haeseong Park; Rashmi K Murthy; Hiroji Iwata; Kenji Tamura; Junji Tsurutani; Alvaro Moreno-Aspitia; Toshihiko Doi; Yasuaki Sagara; Charles Redfern; Ian E Krop; Caleb Lee; Yoshihiko Fujisaki; Masahiro Sugihara; Lin Zhang; Javad Shahidi; Shunji Takahashi, Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 38(28):JCO2001212 - 3352, Jul. 2020
  • Erratum: Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD) (Trials (2020) 21 (391) DOI: 10.1186/s13063-020-04341-y), Toshinari Yamashita; Norikazu Masuda; Shigehira Saji; Kazuhiro Araki; Yoshinori Ito; Toshimi Takano; Masato Takahashi; Junji Tsurutani; Kei Koizumi; Masahiro Kitada; Yasuyuki Kojima; Yasuaki Sagara; Hiroshi Tada; Tsutomu Iwasa; Takayuki Kadoya; Tsuguo Iwatani; Hiroki Hasegawa; Satoshi Morita; Shinji Ohno, Trials, 21(1):503 - 503, Jun. 2020
  • HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers., Li Bob T;Michelini Flavia;Misale Sandra;Cocco Emiliano;Baldino Laura;Cai Yanyan;Shifman Sophie;Tu Hai-Yan;Myers Mackenzie L;Xu Chongrui;Mattar Marissa;Khodos Inna;Little Megan;Qeriqi Besnik;Weitsman Gregory;Wilhem Clare J;Lalani Alshad S;Diala Irmina;Freedman Rachel A;Lin Nancy U;Solit David B;Berger Michael F;Barber Paul R;Ng Tony;Offin Michael;Isbell James M;Jones David R;Yu Helena A;Thyparambil Sheeno;Liao Wei-Li;Bhalkikar Anuja;Cecchi Fabiola;Hyman David M;Lewis Jason S;Buonocore Darren J;Ho Alan L;Makker Vicky;Reis-Filho Jorge S;Razavi Pedram;Arcila Maria E;Kris Mark G;Poirier John T;Shen Ronglai;Tsurutani Junji;Ulaner Gary A;de Stanchina Elisa;Rosen Neal;Rudin Charles M;Scaltriti Maurizio, Cancer discovery, 10(5):674 - 687, May 2020, Peer-reviewed
  • Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors., Tsurutani Junji;Iwata Hiroji;Krop Ian;Jänne Pasi A;Doi Toshihiko;Takahashi Shunji;Park Haeseong;Redfern Charles;Tamura Kenji;Wise-Draper Trisha M;Saito Kaku;Sugihara Masahiro;Singh Jasmeet;Jikoh Takahiro;Gallant Gilles;Li Bob T, Cancer discovery, 10(5):688 - 701, May 2020, Peer-reviewed
  • The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2018 edition., Shimoi Tatsunori;Nagai Shigenori E;Yoshinami Tetsuhiro;Takahashi Masato;Arioka Hitoshi;Ishihara Mikiya;Kikawa Yuichiro;Koizumi Kei;Kondo Naoto;Sagara Yasuaki;Takada Masahiro;Takano Toshimi;Tsurutani Junji;Naito Yoichi;Nakamura Rikiya;Hattori Masaya;Hara Fimikata;Hayashi Naoki;Mizuno Toshiro;Miyashita Minoru;Yamashita Nami;Yamanaka Takashi;Saji Shigehira;Iwata Hiroji;Toyama Tatsuya, Breast cancer (Tokyo, Japan), 27(3):322 - 331, May 2020, Peer-reviewed
  • Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: Study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD), Toshinari Yamashita; Norikazu Masuda; Shigehira Saji; Kazuhiro Araki; Yoshinori Ito; Toshimi Takano; Masato Takahashi; Junji Tsurutani; Kei Koizumi; Masahiro Kitada; Yasuyuki Kojima; Yasuaki Sagara; Hiroshi Tada; Tsutomu Iwasa; Takayuki Kadoya; Tsuguo Iwatani; Hiroki Hasegawa; Satoshi Morita; Shinji Ohno, Trials, 21(1):391 - 391, May 2020, Peer-reviewed
  • Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low-Expressing Advanced Breast Cancer: Results From a Phase Ib Study., Modi Shanu;Park Haeseong;Murthy Rashmi K;Iwata Hiroji;Tamura Kenji;Tsurutani Junji;Moreno-Aspitia Alvaro;Doi Toshihiko;Sagara Yasuaki;Redfern Charles;Krop Ian E;Lee Caleb;Fujisaki Yoshihiko;Sugihara Masahiro;Zhang Lin;Shahidi Javad;Takahashi Shunji, Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 38(17):JCO1902318, Feb. 2020, Peer-reviewed
  • CYP2D6 genotype-guided tamoxifen dosing in hormone receptor-positive metastatic breast cancer (TARGET-1): A randomized, open-label, Phase II study, Kenji Tamura; Chiyo K. Imamura; Toshimi Takano; Shigehira Saji; Takeharu Yamanaka; Kan Yonemori; Masato Takahashi; Junji Tsurutani; Reiki Nishimura; Kazuhiko Sato; Akira Kitani; Naoto T. Ueno; Taisei Mushiroda; Michiaki Kubo; Yasuhiro Fujiwara; Yusuke Tanigawara, Journal of Clinical Oncology, 38(6):558 - 566, Feb. 2020, Peer-reviewed
  • Trastuzumab deruxtecan in previously treated HER2-positive breast cancer, S. Modi; C. Saura; T. Yamashita; Y. H. Park; S. B. Kim; K. Tamura; F. Andre; H. Iwata; Y. Ito; J. Tsurutani; J. Sohn; N. Denduluri; C. Perrin; K. Aogi; E. Tokunaga; S. A. Im; K. S. Lee; S. A. Hurvitz; J. Cortes; C. Lee; S. Chen; L. Zhang; J. Shahidi; A. Yver; I. Krop, New England Journal of Medicine, 382(7):610 - 621, Feb. 2020, Peer-reviewed
  • Effectiveness and safety of eribulin in Japanese patients with HER2-negative, advanced breast cancer: a 2-year post-marketing observational study in a real-world setting., Inoue Kenichi;Takahashi Masato;Mukai Hirofumi;Yamanaka Takashi;Egawa Chiyomi;Sakata Yukinori;Ikezawa Hiroki;Matsuoka Toshiyuki;Tsurutani Junji, Investigational new drugs, 38(5):e, Jan. 2020, Peer-reviewed
  • High expression of olfactomedin-4 is correlated with chemoresistance and poor prognosis in pancreatic cancer., Ohkuma Ryotaro;Yada Erica;Ishikawa Shumpei;Komura Daisuke;Ishizaki Hidenobu;Tamada Koji;Kubota Yutaro;Hamada Kazuyuki;Ishida Hiroo;Hirasawa Yuya;Ariizumi Hirotsugu;Satoh Etsuko;Shida Midori;Watanabe Makoto;Onoue Rie;Ando Kiyohiro;Tsurutani Junji;Yoshimura Kiyoshi;Yokobori Takehiko;Sasada Tetsuro;Aoki Takeshi;Murakami Masahiko;Norose Tomoko;Ohike Nobuyuki;Takimoto Masafumi;Izumizaki Masahiko;Kobayashi Shinichi;Tsunoda Takuya;Wada Satoshi, PloS one, 15(1):e0226707, Jan. 2020, Peer-reviewed
  • U3-1402 sensitizes HER3-expressing tumors to PD-1 blockade by immune activation., HARATANI Koji;YONESAKA Kimio;TAKAMURA Shiki;MAENISHI Osamu;KATO Ryoji;TAKEGAWA Naoki;KAWAKAMI Hisato;TANAKA Kaoru;HAYASHI Hidetoshi;TAKEDA Masayuki;MAEDA Naoyuki;KAGARI Takashi;HIROTANI Kenji;TSURUTANI Junji;NISHIO Kazuto;DOI Katsumi;MIYAZAWA Masaaki;NAKAGAWA Kazuhiko, J Clin Invest, 130(1):374 - 388, Jan. 2020, Peer-reviewed
  • A high number of PD-L1+ CD14+ monocytes in peripheral blood is correlated with shorter survival in patients receiving immune checkpoint inhibitors, Kiyohiro Ando; Kazuyuki Hamada; Midori Shida; Ryotaro Ohkuma; Yutaro Kubota; Atsushi Horiike; Hiroto Matsui; Tomoyuki Ishiguro; Yuya Hirasawa; Hirotsugu Ariizumi; Makoto Watanabe; Rie Onoue; Junji Tsurutani; Kiyoshi Yoshimura; Takuya Tsunoda; Shinichi Kobayashi; Satoshi Wada, Cancer Immunology, Immunotherapy, 70(2):337 - 348, 2020, Peer-reviewed
  • HER2-D16 oncogenic driver mutation confers osimertinib resistance in EGFR mutation-positive non-small cell lung cancer., Yamaoka Toshimitsu;Tsurutani Junji;Sagara Hironori;Ohmori Tohru, Translational lung cancer research, 9(5), 2020, Peer-reviewed
  • A comparative study of curated contents by knowledge-based curation system in cancer clinical sequencing, Kazuko Sakai; Masayuki Takeda; Shigeki Shimizu; Takayuki Takahama; Takeshi Yoshida; Satomi Watanabe; Tsutomu Iwasa; Kimio Yonesaka; Shinichiro Suzuki; Hidetoshi Hayashi; Hisato Kawakami; Yoshikane Nonagase; Kaoru Tanaka; Junji Tsurutani; Kazumasa Saigoh; Akihiko Ito; Tetsuya Mitsudomi; Kazuhiko Nakagawa; Kazuto Nishio, Scientific Reports, 9(1):11340 - 11340, Dec. 2019, Peer-reviewed
  • Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for patients with stage IIIB/IV or postoperative recurrent EGFR mutation-positive non-small-cell lung cancer, H. Yoshioka; M. Shimokawa; T. Seto; S. Morita; Y. Yatabe; I. Okamoto; J. Tsurutani; M. Satouchi; T. Hirashima; S. Atagi; K. Shibata; H. Saito; S. Toyooka; N. Yamamoto; K. Nakagawa; T. Mitsudomi, Annals of Oncology, 30(12):1978 - 1984, Dec. 2019, Peer-reviewed
  • [fam-] trastuzumab deruxtecan, antitumor activity is dependent on HER2 expression level rather than on HER2 amplification., Takegawa Naoki;Tsurutani Junji;Kawakami Hisato;Yonesaka Kimio;Kato Ryoji;Haratani Koji;Hayashi Hidetoshi;Takeda Masayuki;Nonagase Yoshikane;Maenishi Osamu;Nakagawa Kazuhiko, International journal of cancer, 145(12):3414 - 3424, Dec. 2019, Peer-reviewed
  • Multicentre, phase II study of eribulin in combination with S-1 in patients with advanced breast cancer., Iwasa Tsutomu;Tsurutani Junji;Watanabe Satomi;Kato Ryoji;Mizuno Yutaka;Kojima Yasuyuki;Takashima Tsutomu;Matsunami Nobuki;Morimoto Takashi;Yamamura Jun;Ohtani Shoichiro;Tanabe Yuko;Yoshinami Tetsuhiro;Takano Toshimi;Komoike Yoshifumi;Nakagawa Kazuhiko, BMC cancer, 19(1):962, Oct. 2019, Peer-reviewed
  • Plasma Levels of Soluble PD-L1 Correlate With Tumor Regression in Patients With Lung and Gastric Cancer Treated With Immune Checkpoint Inhibitors, ANDO Kiyohiro;HAMADA Kazuyuki;WATANABE Makoto;OHKUMA Ryotaro;SHIDA Midori;ONOUE Rie;KUBOTA Yutaro;MATSUI Hiroto;ISHIGURO Tomoyuki;HIRASAWA Yuya;ARIIZUMI Hirotsugu;TSURUTANI Junji;YOSHIMURA Kiyoshi;TSUNODA Takuya;KOBAYASHI Shinichi;WADA Satoshi, Anticancer Res, 39(9):5195 - 5201, Sep. 2019, Peer-reviewed
  • Blockade of EGFR Activation Promotes TNF-Induced Lung Epithelial Cell Apoptosis and Pulmonary Injury., Yamaoka Toshimitsu;Arata Satoru;Homma Mayumi;Homma Tetsuya;Kusumoto Sojiro;Ando Koichi;Manabe Ryou;Kishino Yasunari;Ohba Motoi;Tsurutani Junji;Takimoto Masafumi;Ohmori Tohru;Sagara Hironori, International journal of molecular sciences, 20(16):E4021, Aug. 2019, Peer-reviewed
  • A phase I/II study of pemetrexed with sirolimus in advanced, previously treated non-small cell lung cancer, Takefumi Komiya; Regan M. Memmott; Gideon M. Blumenthal; Wendy Bernstein; Marc S. Ballas; Roopa De Chowdhury; Guinevere Chun; Cody J. Peer; William D. Figg; David J. Liewehr; Seth M. Steinberg; Giuseppe Giaccone; Eva Szabo; Shigeru Kawabata; Junji Tsurutani; Arun Rajan; Phillip A. Dennis, Translational Lung Cancer Research, 8(3):247 - 257, Jun. 2019, Peer-reviewed
  • Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib., Yamaoka Toshimitsu;Ohba Motoi;Matsunaga Yuki;Tsurutani Junji;Ohmori Tohru, Journal of visualized experiments : JoVE, (148):e, Jun. 2019, Peer-reviewed
  • Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study., Tamura Kenji;Tsurutani Junji;Takahashi Shunji;Iwata Hiroji;Krop Ian E;Redfern Charles;Sagara Yasuaki;Doi Toshihiko;Park Haeseong;Murthy Rashmi K;Redman Rebecca A;Jikoh Takahiro;Lee Caleb;Sugihara Masahiro;Shahidi Javad;Yver Antoine;Modi Shanu, The Lancet. Oncology, 20(6):816 - 826, Jun. 2019, Peer-reviewed
  • Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study., Shitara Kohei;Iwata Hiroji;Takahashi Shunji;Tamura Kenji;Park Haeseong;Modi Shanu;Tsurutani Junji;Kadowaki Shigenori;Yamaguchi Kensei;Iwasa Satoru;Saito Kaku;Fujisaki Yoshihiko;Sugihara Masahiro;Shahidi Javad;Doi Toshihiko, The Lancet. Oncology, 20(6):827 - 836, Jun. 2019, Peer-reviewed
  • Chemotherapy-induced peripheral neuropathy in breast cancer patients treated with eribulin: interim data from a post-marketing observational study., TSURUTANI Junji;SAKATA Yukinori;MATSUOKA Toshiyuki, Breast Cancer, 26(2):235 - 243, Mar. 2019, Peer-reviewed
  • Targeting of the HER2/HER3 signaling axis overcomes ligand-mediated resistance to trastuzumab in HER2-positive breast cancer., Watanabe Satomi;Yonesaka Kimio;Tanizaki Junko;Nonagase Yoshikane;Takegawa Naoki;Haratani Koji;Kawakami Hisato;Hayashi Hidetoshi;Takeda Masayuki;Tsurutani Junji;Nakagawa Kazuhiko, Cancer medicine, 8(3):1258 - 1268, Mar. 2019, Peer-reviewed
  • aCGH Analysis of Predictive Biomarkers for Response to Bevacizumab plus Oxaliplatin- or Irinotecan-Based Chemotherapy in Patients with Metastatic Colorectal Cancer, Yoshihiko Fujita; Masataka Taguri; Kentaro Yamazaki; Junji Tsurutani; Kazuko Sakai; Takahiro Tsushima; Michitaka Nagase; Hiroshi Tamagawa; Shinya Ueda; Takao Tamura; Yasushi Tsuji; Kohei Murata; Koichi Taira; Tadamichi Denda; Toshikazu Moriwaki; Sadao Funai; Takako Eguchi Nakajima; Kei Muro; Akihito Tsuji; Motoki Yoshida; Koichi Suyama; Takuya Kurimoto; Naotoshi Sugimoto; Eishi Baba; Nobuhiko Seki; Mikio Sato; Takaya Shimura; Narikazu Boku; Ichinosuke Hyodo; Takeharu Yamanaka; Kazuto Nishio, Oncologist, 24(3):327 - 337, Mar. 2019, Peer-reviewed
  • KRAS and EGFR Amplifications Mediate Resistance to Rociletinib and Osimertinib in Acquired Afatinib-Resistant NSCLC Harboring Exon 19 Deletion/T790M in EGFR., NAKATANI Kaori;YAMAOKA Toshimitsu;OHBA Motoi;FUJITA Ken-ichi;ARATA Satoru;KUSUMOTO Sojiro;TAKI (TAKEMOTO) Iori;KAMEI Daisuke;IWAI Shinichi;TSURUTANI Junji;OHMORI Tohru, Mol Cancer Ther, 18(1):112 - 126, Jan. 2019, Peer-reviewed
  • Mutational activation of the epidermal growth factor receptor down-regulates major histocompatibility complex class I expression via the extracellular signal-regulated kinase in non-small cell lung cancer., WATANABE Satomi;HAYASHI Hidetoshi;HARATANI Koji;SHIMIZU Shigeki;TANIZAKI Junko;SAKAI Kazuko;KAWAKAMI Hisato;YONESAKA Kimio;TSURUTANI Junji;TOGASHI Yosuke;NISHIO Kazuto;ITO Akihiko;NAKAGAWA Kazuhiko, Cancer Sci, 110(1):52 - 60, Jan. 2019, Peer-reviewed
  • HER2 genomic amplification in circulating tumor DNA and estrogen receptor positivity predict primary resistance to trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer, Hitomi Sakai; Junji Tsurutani; Tsutomu Iwasa; Yoshifumi Komoike; Kazuko Sakai; Kazuto Nishio; Kazuhiko Nakagawa, Breast Cancer, 25(5):605 - 613, Sep. 2018, Peer-reviewed
  • A randomized phase II trial of trastuzumab plus capecitabine versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and taxanes: WJOG6110B/ELTOP, Toshimi Takano; Junji Tsurutani; Masato Takahashi; Takeharu Yamanaka; Kazuko Sakai; Yoshinori Ito; Junya Fukuoka; Hideharu Kimura; Hidetaka Kawabata; Kenji Tamura; Koji Matsumoto; Kenjiro Aogi; Kazuhiko Sato; Kazuto Nishio; Kazuhiko Nakagawa; Toshiaki Saeki, Breast, 40:67 - 75, Aug. 2018, Peer-reviewed
  • Safety and effectiveness of eribulin in Japanese patients with locally advanced or metastatic breast cancer: a post-marketing observational study, Junichiro Watanabe; Yoshinori Ito; Shozo Ohsumi; Mitsuhiro Mizutani; Hideya Tashiro; Kenichi Sakurai; Masato Takahashi; Tsuyoshi Saito; Junji Tsurutani; Hirofumi Mukai; Tetsuhiro Yoshinami; Shintaro Takao; Yasuhisa Yamamoto; Toshiyuki Matsuoka; Hirotaka Iwase; Hiroji Iwata; Seigo Nakamura; Toshiaki Saeki, Investigational New Drugs, 35(6):791 - 799, Dec. 2017, Peer-reviewed
  • T790M-selective EGFR-TKI combined with dasatinib as an optimal strategy for overcoming EGFR-TKI resistance in T790M-positive non–small cell lung cancer, Satomi Watanabe; Takeshi Yoshida; Hisato Kawakami; Naoki Takegawa; Junko Tanizaki; Hidetoshi Hayashi; Masayuki Takeda; Kimio Yonesaka; Junji Tsurutani; Kazuhiko Nakagawa, Molecular Cancer Therapeutics, 16(11):2563 - 2571, Nov. 2017, Peer-reviewed
  • DS-8201a, a new HER2-targeting antibody–drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2-positive gastric cancer T-DM1 resistance, Naoki Takegawa; Yoshikane Nonagase; Kimio Yonesaka; Kazuko Sakai; Osamu Maenishi; Yusuke Ogitani; Takao Tamura; Kazuto Nishio; Kazuhiko Nakagawa; Junji Tsurutani, International Journal of Cancer, 141(8):1682 - 1689, Oct. 2017, Peer-reviewed
  • Prospective replication study implicates the catechol-o-methyltransferase val158met polymorphism as a biomarker for the response to morphine in patients with cancer, Hiromichi Matsuoka; Chihiro Makimura; Atsuko Koyama; Yoshihiko Fujita; Junji Tsurutani; Kiyohiro Sakai; Ryo Sakamoto; Kazuto Nishio; Kazuhiko Nakagawa, Biomedical Reports, 7(4):380 - 384, Oct. 2017, Peer-reviewed
  • Selection of opioids for cancer-related pain using a biomarker: A randomized, multi-institutional, open-label trial (RELIEF study), Hiromichi Matsuoka; Junji Tsurutani; Yasutaka Chiba; Yoshihiko Fujita; Masato Terashima; Takeshi Yoshida; Kiyohiro Sakai; Yoichi Otake; Atsuko Koyama; Kazuto Nishio; Kazuhiko Nakagawa, BMC Cancer, 17(1):674 - 674, Oct. 2017
  • Increased risk of SSEs in bone-only metastatic breast cancer patients treated with zoledronic acid, Masashi Yanae; Shinichiro Fujimoto; Kaori Tane; Maki Tanioka; Kimiko Fujiwara; Masanobu Tsubaki; Yuzuru Yamazoe; Yoshiyuki Morishima; Yasutaka Chiba; Shintaro Takao; Yoshifumi Komoike; Junji Tsurutani; Kazuhiko Nakagawa; Shozo Nishida, Journal of Bone Oncology, 8(8):18 - 22, Sep. 2017, Peer-reviewed
  • Lentinula edodes mycelia extract plus adjuvant chemotherapy for breast cancer patients: Results of a randomized study on host quality of life and immune function improvement, Yukiko Nagashima; Shigehumi Yoshino; Shigeru Yamamoto; Noriko Maeda; Tatsuya Azumi; Yoshifumi Komoike; Kiyotaka Okuno; Tsutomu Iwasa; Junji Tsurutani; Kazuhiko Nakagawa; Oka Masaaki; Nagano Hiroaki, MOLECULAR AND CLINICAL ONCOLOGY, 7(3):359 - 366, Sep. 2017, Peer-reviewed
  • Expectation of a Decrease in Pain Affects the Prognosis of Pain in Cancer Patients: a Prospective Cohort Study of Response to Morphine, Hiromichi Matsuoka; Kazuhiro Yoshiuchi; Atsuko Koyama; Chihiro Makimura; Yoshihiko Fujita; Junji Tsurutani; Kiyohiro Sakai; Ryo Sakamoto; Kazuto Nishio; Kazuhiko Nakagawa, International Journal of Behavioral Medicine, 24(4):535 - 541, Aug. 2017, Peer-reviewed
  • Gemcitabine and Vinorelbine Combination Chemotherapy in Taxane-Pretreated Patients with Metastatic Breast Cancer: A Phase II Study of the Kinki Multidisciplinary Breast Oncology Group (KMBOG) 1015, Jun Yamamura; Norikazu Masuda; Daigo Yamamoto; Shigeru Tsuyuki; Masahide Yamaguchi; Satoru Tanaka; Junji Tsurutani; Shinya Tokunaga; Katsuhide Yoshidome; Makiko Mizutani; Toyokazu Aono; Asako Ooe; Hirokazu Tanino; Nobuki Matsunami; Hiroyuki Yasojima; Takahiro Nakayama; Yukihiro Nishida, Chemotherapy, 62(5):307 - 313, Aug. 2017, Peer-reviewed
  • Incidence of carnitine deficiency in patients with cancer pain: A pilot study, Kiyohiro Sakai; Hiromichi Matsuoka; Yoichi Ohtake; Chihiro Makimura; Hiroaki Izumi; Yoshihiko Fujita; Masatomo Otsuka; Junji Tsurutani; Kazuto Nishio; Kazuhiko Nakagawa; Atsuko Koyama, MOLECULAR AND CLINICAL ONCOLOGY, 6(3):331 - 333, Mar. 2017, Peer-reviewed
  • Clinical evaluation of palliative chemoradiotherapy for metastatic esophageal cancer, Hiroto Ueda; Masayuki Takeda; Shinya Ueda; Hisato Kawakami; Tatsuya Okuno; Naoki Takegawa; Hidetoshi Hayashi; Junji Tsurutani; Takao Tamura; Kazuki Ishikawa; Yasumasa Nishimura; Kazuhiko Nakagawa, Oncotarget, 8(46):80286 - 80294, 2017, Peer-reviewed
  • Phase 1 study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced solid tumors, Toshio Shimizu; Takashi Seto; Fumihiko Hirai; Mitsuhiro Takenoyama; Kaname Nosaki; Junji Tsurutani; Hiroyasu Kaneda; Tsutomu Iwasa; Hisato Kawakami; Kazuo Noguchi; Takashi Shimamoto; Kazuhiko Nakagawa, Investigational New Drugs, 34(3):347 - 354, Jun. 2016, Peer-reviewed
  • Successful human epidermal growth receptor 2-targeted therapy beyond disease progression for extramammary Paget’s disease, Satomi Watanabe; Masayuki Takeda; Takayuki Takahama; Tsutomu Iwasa; Junji Tsurutani; Junko Tanizaki; Toshio Shimizu; Kazuko Sakai; Yoshitaka Wada; Noritaka Isogai; Kazuto Nishio; Kazuhiko Nakagawa, Investigational New Drugs, 34(3):394 - 396, Jun. 2016
  • 【日本乳癌学会乳癌診療ガイドライン2015年版】乳癌の薬物療法に関する日本乳癌学会乳癌診療ガイドライン2015年版(【Japanese Breast Cancer Society Guidelines 2015】The Japanese Breast Cancer Society Clinical Practice Guideline for systemic treatment of breast cancer, 2015 edition), Aihara Tomohiko;Toyama Tatsuya;Takahashi Masato;Yamamoto Yutaka;Hara Fumikata;Akabane Hiromitsu;Fujisawa Tomomi;Ishikawa Takashi;Nagai Shigenori;Nakamura Rikiya;Tsurutani Junji;Ito Yoshinori;Mukai Hirofumi;The Japanese Breast Cancer Society, Breast Cancer, 23(3):329, May 2016
  • Afatinib-refractory brain metastases from EGFR-mutant non-small-cell lung cancer successfully controlled with erlotinib: A case report, Yoshikane Nonagase; Kunio Okamoto; Tsutomu Iwasa; Takeshi Yoshida; Kaoru Tanaka; Masayuki Takeda; Hiroyasu Kaneda; Toshio Shimizu; Junji Tsurutani; Kazuhiko Nakagawa, Anti-Cancer Drugs, 27(3):251 - 253, Mar. 2016
  • Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): An open-label, non-inferiority, randomised phase 3 trial, Tsutomu Takashima; Hirofumi Mukai; Fumikata Hara; Nobuaki Matsubara; Tsuyoshi Saito; Toshimi Takano; Youngjin Park; Tatsuya Toyama; Yasuo Hozumi; Junji Tsurutani; Shigeru Imoto; Takanori Watanabe; Yoshiaki Sagara; Reiki Nishimura; Kojiro Shimozuma; Yasuo Ohashi, The Lancet Oncology, 17(1):90 - 98, Jan. 2016, Peer-reviewed
  • HER2 genomic amplification in circulating tumor DNA from patients with cetuximab-resistant colorectal cancer, Naoki Takegawa; Kimio Yonesaka; Kazuko Sakai; Hiroto Ueda; Satomi Watanabe; Yoshikane Nonagase; Tatsuya Okuno; Masayuki Takeda; Osamu Maenishi; Junji Tsurutani; Taroh Satoh; Isamu Okamoto; Kazuto Nishio; Takao Tamura; Kazuhiko Nakagawa, Oncotarget, 7(3):3453 - 3460, 2016, Peer-reviewed
  • Heregulin-expressing HER2-positive breast and gastric cancer exhibited heterogeneous susceptibility to the anti-HER2 agents lapatinib, trastuzumab and T-DM1, Yoshikane Nonagase; Kimio Yonesaka; Hisato Kawakami; Satomi Watanabe; Koji Haratani; Takayuki Takahama; Naoki Takegawa; Hiroto Ueda; Junko Tanizaki; Hidetoshi Hayashi; Takeshi Yoshida; Masayuki Takeda; Yasutaka Chiba; Takao Tamura; Kazuhiko Nakagawa; Junji Tsurutani, Oncotarget, 7(51):84860 - 84871, 2016, Peer-reviewed
  • Randomized, optimal dose finding, phase II study of tri-weekly nabpaclitaxel in patients with metastatic breast cancer (ABROAD)., Hara F; Takashima T; Tsurutani J; Saito T; Taira N; Kashiwabara K; Aihara T; Mukai H, Journal of Clinical Trials, 6(3):267 - 267, 2016
  • Phase I study of weekly nab-paclitaxel combined with S-1 in patients with human epidermal growth factor receptor type 2-negative metastatic breast cancer, Junji Tsurutani; Katsumasa Kuroi; Tsutomu Iwasa; Masaki Miyazaki; Shinichi Nishina; Chihiro Makimura; Junko Tanizaki; Kunio Okamoto; Toshinari Yamashita; Tomoyuki Aruga; Takashi Shigekawa; Yoshifumi Komoike; Toshiaki Saeki; Kazuhiko Nakagawa, Cancer Science, 106(6):734 - 739, Jun. 2015, Peer-reviewed
  • Extended RAS and BRAF mutation analysis using next-generation sequencing, Kazuko Sakai; Junji Tsurutani; Takeharu Yamanaka; Azusa Yoneshige; Akihiko Ito; Yosuke Togashi; Marco A. De Velasco; Masato Terashima; Yoshihiko Fujita; Shuta Tomida; Takao Tamura; Kazuhiko Nakagawa; Kazuto Nishio, PLoS ONE, 10(5):e0121891, May 2015, Peer-reviewed
  • Phase i study of amatuximab, a novel monoclonal antibody to mesothelin, in Japanese patients with advanced solid tumors, Yasuhito Fujisaka; Takayasu Kurata; Kaoru Tanaka; Toshihiro Kudo; Kunio Okamoto; Junji Tsurutani; Hiroyasu Kaneda; Isamu Okamoto; Masayuki Namiki; Chifumi Kitamura; Kazuhiko Nakagawa, Investigational New Drugs, 33(2):380 - 388, Apr. 2015, Peer-reviewed
  • A phase i dose-escalation study of eribulin and S-1 for metastatic breast cancer, T. Sakiyama; J. Tsurutani; T. Iwasa; H. Kawakami; Y. Nonagase; T. Yoshida; K. Tanaka; Y. Fujisaka; T. Kurata; Y. Komoike; K. Nishio; K. Nakagawa, British Journal of Cancer, 112(5):819 - 824, Mar. 2015, Peer-reviewed
  • Tolerability of nintedanib (BIBF 1120) in combination with docetaxel: A phase 1 study in japanese patients with previously treated non-small-cell lung cancer, Isamu Okamoto; Masaki Miyazaki; Masayuki Takeda; Masaaki Terashima; Koichi Azuma; Hidetoshi Hayashi; Hiroyasu Kaneda; Takayasu Kurata; Junji Tsurutani; Takashi Seto; Fumihiko Hirai; Koichi Konishi; Akiko Sarashina; Nobutaka Yagi; Rolf Kaiser; Kazuhiko Nakagawa, Journal of Thoracic Oncology, 10(2):346 - 352, Feb. 2015, Peer-reviewed
  • 【日本乳癌学会ガイドライン2013】乳癌の全身治療に関する日本乳癌学会診療ガイドライン(【Japanese Breast Cancer Society Guidelines 2013】The Japanese Breast Cancer Society Clinical Practice Guideline for systemic treatment of breast cancer), Mukai Hirofumi;Aihara Tomohiko;Yamamoto Yutaka;Takahashi Masato;Toyama Tatsuya;Sagara Yasuaki;Yamaguchi Hiroshi;Akabane Hiromitsu;Tsurutani Junji;Hara Fumikata;Fujisawa Tomomi;Yamamoto Naohito;Ohsumi Shozo, Breast Cancer, 22(1):5, Jan. 2015
  • Pathologic complete response after neoadjuvant chemotherapy in HER2-overexpressing breast cancer according to hormonal receptor status, Maki Tanioka; Masaoki Sasaki; Akihiko Shimomura; Makoto Fujishima; Mihoko Doi; Kazuo Matsuura; Toshiko Sakuma; Kenichi Yoshimura; Toshiaki Saeki; Masahiro Ohara; Junji Tsurutani; Masahiro Watatani; Toshimi Takano; Hidetaka Kawabata; Hirofumi Mukai; Yoichi Naito; Koichi Hirokaga; Shintaro Takao; Hironobu Minami, Breast, 23(4):466 - 472, Aug. 2014, Peer-reviewed
  • Phase II study of S-1 in combination with trastuzumab for HER2-positive metastatic breast cancer, Tsutomu Takashima; Takahiro Nakayama; Katsuhide Yoshidome; Hidemi Kawajiri; Shunji Kamigaki; Junji Tsurutani; Takashi Arai; Toshikazu Ito; Yoshihumi Komoike; Takako Doi; Norikazu Masuda; Keisuke Miyauchi; Yasuo Miyoshi; Junichi Sakamoto; Satoshi Morita; Tetsuya Taguchi, Anticancer Research, 34(7):3583 - 3588, Jul. 2014, Peer-reviewed
  • Risk factors for cisplatin-induced nephrotoxicity and potential of magnesium supplementation for renal protection, Yasuhiro Kidera; Hisato Kawakami; Tsutomu Sakiyama; Kunio Okamoto; Kaoru Tanaka; Masayuki Takeda; Hiroyasu Kaneda; Shin Ichi Nishina; Junji Tsurutani; Kimiko Fujiwara; Morihiro Nomura; Yuzuru Yamazoe; Yasutaka Chiba; Shozo Nishida; Takao Tamura; Kazuhiko Nakagawa, PLoS ONE, 9(7):e101902, Jul. 2014, Peer-reviewed
  • Rapamycin downregulates thymidylate synthase and potentiates the activity of pemetrexed in non-small cell lung cancer, Shigeru Kawabata; Chun Te Chiang; Junji Tsurutani; Hideaki Shiga; Matthew L. Arwood; Takefumi Komiya; Joell J. Gills; Regan M. Memmott; Phillip A. Dennis, Oncotarget, 5(4):1062 - 1070, 2014, Peer-reviewed
  • Synergistic antitumor effects of S-1 with eribulin in vitro and in vivo for triple-negative breast cancer cell lines, Masato Terashima; Kazuko Sakai; Yosuke Togashi; Hidetoshi Hayashi; Marco A. De Velasco; Junji Tsurutani; Kazuto Nishio, SpringerPlus, 3(1):1 - 11, 2014, Peer-reviewed
  • Regression of brain metastases from breast cancer with eribulin: A case report, Hiromichi Matsuoka; Junji Tsurutani; Junko Tanizaki; Tsutomu Iwasa; Yoshifumi Komoike; Atsuko Koyama; Kazuhiko Nakagawa, BMC Research Notes, 6(1):541 - 541, Dec. 2013
  • A phase i study of S-1 with concurrent radiotherapy in elderly patients with locally advanced non-small cell lung cancer, Yoshikazu Hasegawa; Isamu Okamoto; Ken Takezawa; Masaaki Miyazaki; Junji Tsurutani; Kimio Yonesaka; Ryotaroh Morinaga; Asuka Tsuya; Masaaki Terashima; Toshihiro Kudoh; Koichi Azuma; Takayasu Kurata; Tatsuyuki Nishikawa; Masahiro Fukuoka; Yasumasa Nishimura; Kazuhiko Nakagawa, Investigational New Drugs, 31(3):599 - 604, Jun. 2013, Peer-reviewed
  • Phase II study of bi-weekly irinotecan for patients with previously treated HER2-negative metastatic breast cancer: KMBOG0610B, Hidetoshi Hayashi; Junji Tsurutani; Taro Satoh; Norikazu Masuda; Wataru Okamoto; Ryotaro Morinaga; Masaaki Terashima; Masaki Miyazaki; Isamu Okamoto; Yukihiro Nishida; Shusei Tominaga; Yukihiko Tokunaga; Masahide Yamaguchi; Junichi Sakamoto; Takahiro Nakayama; Kazuhiko Nakagawa, Breast Cancer, 20(2):131 - 136, Apr. 2013, Peer-reviewed
  • Practical Use of Gemcitabine and Cisplatin Combination Therapy as First-Line Treatment for Japanese Patients with Advanced Biliary Tract Cancer, Kawakami H; Okamoto I; Okamoto W; Takeda M; Ueda S; Kudo T; Nishina S; Fujisaka Y; Miyazaki M; Tsurutani J; Kurata T; Nakagawa K, Journal of Cancer Therapy, 4:1068 - 1073, 2013, Peer-reviewed
  • [Resistant mechanisms against breast cancer treatment and therapeutic strategies]., Junko Tanizaki; Junji Tsurutani, Nihon rinsho. Japanese journal of clinical medicine, 70 Suppl 8:336 - 340, Nov. 2012
  • Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC, Masayuki Takeda; Isamu Okamoto; Junji Tsurutani; Naoki Oiso; Akira Kawada; Kazuhiko Nakagawa, Japanese Journal of Clinical Oncology, 42(6):528 - 533, Jun. 2012, Peer-reviewed
  • Expression changes in arrestin β 1 and genetic variation in catechol-O-methyltransferase are biomarkers for the response to morphine treatment in cancer patients, Hiromichi Matsuoka; Tokuzo Arao; Chihiro Makimura; Masayuki Takeda; Hidemi Kiyota; Junji Tsurutani; Yoshihiko Fujita; Kazuko Matsumoto; Hideharu Kimura; Masatomo Otsuka; Atsuko Koyama; Chiyo K. Imamura; Yusuke Tanigawara; Takeharu Yamanaka; Kyoko Tanaka; Kazuto Nishio; Kazuhiko Nakagawa, Oncology Reports, 27(5):1393 - 1399, May 2012, Peer-reviewed
  • Pilot study of duloxetine for cancer patients with neuropathic pain non-responsive to pregabalin, Hiromichi Matsuoka; Chihiro Makimura; Atsuko Koyama; Masatomo Otsuka; Wataru Okamoto; Yasuhito Fujisaka; Hiroyasu Kaneda; Junji Tsurutani; Kazuhiko Nakagawa, Anticancer Research, 32(5):1805 - 1810, May 2012, Peer-reviewed
  • Feasibility study of two schedules of sunitinib in combination with pemetrexed in patients with advanced solid tumors, Isamu Okamoto; Toshio Shimizu; Masaki Miyazaki; Junji Tsurutani; Yasuko Ichikawa; Masaki Terashima; Masayuki Takeda; Soichi Fumita; Emiko Ohki; Nobuyuki Kimura; Junichi Hashimoto; Kazuhiko Nakagawa, Investigational New Drugs, 30(2):639 - 646, Apr. 2012, Peer-reviewed
  • NDRG1/Cap43/Drg-1 may predict tumor angiogenesis and poor outcome in patients with lung cancer, Koichi Azuma; Akihiko Kawahara; Satoshi Hattori; Tomoki Taira; Junji Tsurutani; Kosuke Watari; Tomohiro Shibata; Yuichi Murakami; Shinzo Takamori; Mayumi Ono; Hiroto Izumi; Masayoshi Kage; Takashi Yanagawa; Kazuhiko Nakagawa; Tomoaki Hoshino; Michihiko Kuwano, Journal of Thoracic Oncology, 7(5):779 - 789, 2012, Peer-reviewed
  • Perspectives in drug development for cancer therapy in Asia, Kazuhiko Nakagawa; Junji Tsurutani, Chinese Clinical Oncology, 1(2):17 - 17, 2012
  • Prospective study evaluating the plasma concentrations of twenty-six cytokines and response to morphine treatment in cancer patients, Chihiro Makimura; Tokuzo Arao; Hiromichi Matsuoka; Masayuki Takeda; Hidemi Kiyota; Junji Tsurutani; Yoshihiko Fujita; Kazuko Matsumoto; Hideharu Kimura; Masatomo Otsuka; Atsuko Koyama; Chiyo K. Imamura; Takeharu Yamanaka; Kyoko Tanaka; Kazuto Nishio; Kazuhiko Nakagawa, Anticancer Research, 31(12):4561 - 4568, Dec. 2011, Peer-reviewed
  • Loss of cytoplasmic CDK1 predicts poor survival in human lung cancer and confers chemotherapeutic resistance, Chunyu Zhang; Abdel G. Elkahloun; Matthew Robertson; Joell J. Gills; Junji Tsurutani; Joanna H. Shih; Junya Fukuoka; M. Christine Hollander; Curtis C. Harris; William D. Travis; Jin Jen; Phillip A. Dennis, PLoS ONE, 6(8):e23849, Aug. 2011, Peer-reviewed
  • High-dose dexamethasone plus antihistamine prevents colorectal cancer patients treated with modified FOLFOX6 from hypersensitivity reactions induced by oxaliplatin, Yasuhiro Kidera; Taroh Satoh; Shinya Ueda; Wataru Okamoto; Isamu Okamoto; Soichi Fumita; Kimio Yonesaka; Hidetoshi Hayashi; Chihiro Makimura; Kunio Okamoto; Hidemi Kiyota; Junji Tsurutani; Masaki Miyazaki; Masahiro Yoshinaga; Kimiko Fujiwara; Yuzuru Yamazoe; Kenzo Moriyama; Masanobu Tsubaki; Yasutaka Chiba; Shozo Nishida; Kazuhiko Nakagawa, International Journal of Clinical Oncology, 16(3):244 - 249, Jun. 2011, Peer-reviewed
  • Switching addictions between HER2 and FGFR2 in HER2-positive breast tumor cells: FGFR2 as a potential target for salvage after lapatinib failure, Koichi Azuma; Junji Tsurutani; Kazuko Sakai; Hiroyasu Kaneda; Yasuhito Fujisaka; Masayuki Takeda; Masahiro Watatani; Tokuzo Arao; Taroh Satoh; Isamu Okamoto; Takayasu Kurata; Kazuto Nishio; Kazuhiko Nakagawa, Biochemical and Biophysical Research Communications, 407(1):219 - 224, Apr. 2011, Peer-reviewed
  • Transient effectiveness of an oral 5-fluorouracil derivative, S-1, for epirubicin, cyclophosphamide and paclitaxel refractory skin metastases from possible occult breast cancer in a male, Ayaka Hirao; Naoki Oiso; Junji Tsurutani; Masatomo Kimura; Masahiro Watatani; Kazuhiko Nakagawa; Akira Kawada, Case Reports in Dermatology, 3(1):42 - 48, Jan. 2011
  • Dose-escalation study of pemetrexed in combination with carboplatin followed by pemetrexed maintenance therapy for advanced non-small cell lung cancer, Isamu Okamoto; Koji Takeda; Haruko Daga; Masaki Miyazaki; Kimio Yonesaka; Hidemi Kiyota; Junji Tsurutani; Shinya Ueda; Yasuko Ichikawa; Masayuki Takeda; Risa Sekiguchi; Kiyomi Tominaga; Sotaro Enatsu; Yoshihiro Nambu; Kazuhiko Nakagawa, Lung Cancer, 70(2):168 - 173, Nov. 2010, Peer-reviewed
  • A phase I study of gemcitabine plus irinotecan for advanced NSCLC: Japan Clinical Oncology Group trial (JCOG9904), Takayasu Kurata; Nobuyuki Yamamoto; Takefumi Komiya; Junji Tsurutani; Masaki Miyazaki; Kenji Tamura; Koji Takeda; Kazuhiko Nakagawa; Masahiro Fukuoka, Japanese Journal of Clinical Oncology, 40(10):992 - 994, Jun. 2010, Peer-reviewed
  • FOXQ1 is overexpressed in colorectal cancer and enhances tumorigenicity and tumor growth, Hiroyasu Kaneda; Tokuzo Arao; Kaoru Tanaka; Daisuke Tamura; Keiichi Aomatsu; Kanae Kudo; Kazuko Sakai; Marco A. De Velasco; Kazuko Matsumoto; Yoshihiko Fujita; Yasuhide Yamada; Junji Tsurutani; Isamu Okamoto; Kazuhiko Nakagawa; Kazuto Nishio, Cancer Research, 70(5):2053 - 2063, Mar. 2010, Peer-reviewed
  • Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial, Tetsuya Mitsudomi; Satoshi Morita; Yasushi Yatabe; Shunichi Negoro; Isamu Okamoto; Junji Tsurutani; Takashi Seto; Miyako Satouchi; Hirohito Tada; Tomonori Hirashima; Kazuhiro Asami; Nobuyuki Katakami; Minoru Takada; Hiroshige Yoshioka; Kazuhiko Shibata; Shinzoh Kudoh; Eiji Shimizu; Hiroshi Saito; Shinichi Toyooka; Kazuhiko Nakagawa; Masahiro Fukuoka, The Lancet Oncology, 11(2):121 - 128, Feb. 2010, Peer-reviewed
  • Lemierre's syndrome followed by acute respiratory distress syndrome successfully rescued by antibiotics and hemoperfusion with polymyxin b-immobilized fiber, Takahiro Takazono; Koichi Izumikawa; Junji Tsurutani; Akitaka Tanaka; Tomoyuki Kakugawa; Yuichi Fukuda; Masataka Saito; Shintaro Kurihara; Yoshifumi Imamura; Masafumi Seki; Hiroshi Kakeya; Yoshihiro Yamamoto; Katsunori Yanagihara; Shigeru Kohno, Japanese Journal of Infectious Diseases, 62(2):133 - 136, 2009
  • Zoledronic acid-induced regression of multiple metastases at nonskeletal sites, K. Okamoto; J. Tsurutani; M. Terashima; I. Okamoto; K. Nakagawa, Annals of Oncology, 20(4):796 - 797, 2009
  • Nelfinavir, a lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and invivo, Joell J. Gills; Jaclyn LoPiccolo; Junji Tsurutani; Robert H. Shoemaker; Carolyn J.M. Best; Mones S. Abu-Asab; Jennifer Borojerdi; Noel A. Warfel; Erin R. Gardner; Matthew Danish; M. Christine Hollander; Shigeru Kawabata; Maria Tsokos; William D. Figg; Patricia S. Steeg; Phillip A. Dennis, Clinical Cancer Research, 13(17):5183 - 5194, Sep. 2007, Peer-reviewed
  • Identification of a highly effective rapamycin schedule that markedly reduces the size, multiplicity, and phenotypic progression of tobacco carcinogen - Induced murine lung tumors, Courtney A. Granville; Noel Warfel; Junji Tsurutani; M. Christine Hollander; Matthew Robertson; Stephen D. Fox; Timothy D. Veenstra; Haleem J. Issaq; R. Ilona Linnoila; Phillip A. Dennis, Clinical Cancer Research, 13(7):2281 - 2289, Apr. 2007, Peer-reviewed
  • Prognostic significance of clinical factors and Akt activation in patients with bronchioloalveolar carcinoma, Junji Tsurutani; Seth M. Steinberg; Marc Ballas; Matthew Robertson; Jaclyn LoPiccolo; Hiroshi Soda; Shigeru Kohno; Valgardur Egilsson; Phillip A. Dennis, Lung Cancer, 55(1):115 - 121, Jan. 2007, Peer-reviewed
  • Phase II study of irinotecan combined with carboplatin in previously untreated small-cell lung cancer, A. Kinoshita; M. Fukuda; H. Soda; S. Nagashima; M. Fukuda; H. Takatani; M. Kuba; Y. Nakamura; J. Tsurutani; S. Kohno; M. Oka, British Journal of Cancer, 94(9):1267 - 1271, May 2006, Peer-reviewed
  • Evaluation of two phosphorylation sites improves the prognostic significance of Akt activation in non-small-cell lung cancer tumors, Junji Tsurutani; Junya Fukuoka; Hiroko Tsurutani; Joanna H. Shih; Stephen M. Hewitt; William D. Travis; Jin Jen; Phillip A. Dennis, Journal of Clinical Oncology, 24(2):306 - 314, Jan. 2006, Peer-reviewed
  • Phase II study of weekly paclitaxel for relapsed and refractory small cell lung cancer, Nobuyuki Yamamoto; Junji Tsurutani; Naruo Yoshimura; Gyo Asai; Azusa Moriyama; Kazuhiko Nakagawa; Shinzo Kudoh; Minoru Takada; Yoshiaki Minato; Masahiro Fukuoka, Anticancer Research, 26(1 B):777 - 781, Jan. 2006, Peer-reviewed
  • Gefitinib, an EGFR tyrosine kinase inhibitor, directly inhibits the function of P-glycoprotein in multidrug resistant cancer cells, Takeshi Kitazaki; Mikio Oka; Yoichi Nakamura; Junji Tsurutani; Seiji Doi; Masa Yasunaga; Masaaki Takemura; Hikaru Yabuuchi; Hiroshi Soda; Shigeru Kohno, Lung Cancer, 49(3):337 - 343, Sep. 2005, Peer-reviewed
  • Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy, Junji Tsurutani; Kip A. West; Jacqueline Sayyah; Joell J. Gills; Phillip A. Dennis, Cancer Research, 65(18):8423 - 8432, Sep. 2005, Peer-reviewed
  • Mect1-Maml2 fusion oncogene linked to the aberrant activation of cyclic AMP/CREB regulated genes, Amy Coxon; Ester Rozenblum; Yoon Soo Park; Nina Joshi; Junji Tsurutani; Phillip A. Dennis; Ilan R. Kirsch; Frederic J. Kaye, Cancer Research, 65(16):7137 - 7144, Aug. 2005, Peer-reviewed
  • Tobacco components stimulate Akt-dependent proliferation and NFκB-dependent survival in lung cancer cells, Junji Tsurutani; S. Sianna Castillo; John Brognard; Courtney A. Granville; Chunyu Zhang; Joell J. Gills; Jacqueline Sayyah; Phillip A. Dennis, Carcinogenesis, 26(7):1182 - 1195, Jul. 2005, Peer-reviewed
  • Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance, Yoichi Nakamura; Mikio Oka; Hiroshi Soda; Ken Shiozawa; Megumi Yoshikawa; Akiko Itoh; Yoji Ikegami; Junji Tsurutani; Katsumi Nakatomi; Takeshi Kitazaki; Seiji Doi; Hisahiro Yoshida; Shigeru Kohno, Cancer Research, 65(4):1541 - 1546, Feb. 2005, Peer-reviewed
  • Induction of preneoplastic lung lesions in guinea pigs by cigarette smoke inhalation and their exacerbation by high dietary levels of vitamins C and E, Emerich S. Fiala; Ock Soon Sohn; Chung Xiou Wang; Eleanore Seibert; Junji Tsurutani; Phillip A. Dennis; Karam El-Bayoumy; Rama S. Sodum; Dhimant Desai; Joel Reinhardt; Cesar Aliaga, Carcinogenesis, 26(3):605 - 612, 2005, Peer-reviewed
  • Inhibition of EGFR, HER2 and HER3 signaling with AZD8931 alone and in combination with paclitaxel: Phase I study in Japanese patients with advanced solid malignancies and advanced breast cancer, Takayasu Kurata; Junji Tsurutani; Yasuhito Fujisaka; Wataru Okamoto; Hidetoshi Hayashi; Hisato Kawakami; Eisei Shin; Nobuya Hayashi; Kazuhiko Nakagawa, Investigational New Drugs, 32(5):946 - 954, 2005, Peer-reviewed
  • Phase II study of irinotecan combined with carboplatin in previously untreated non-small-cell lung cancer, Minoru Fukuda; Mikio Oka; Hiroshi Soda; Akitoshi Kinoshita; Masaaki Fukuda; Seiji Nagashima; Mutsuo Kuba; Hiroshi Takatani; Junji Tsurutani; Yoichi Nakamura; Takashi Kasai; Yuichi Inoue; Yoshifumi Soejima; Shigeru Kohno, Cancer Chemotherapy and Pharmacology, 54(6):573 - 577, Dec. 2004, Peer-reviewed
  • The histone deacetylase inhibitor FR901228 induces caspase-dependent apoptosis via the mitochondrial pathway in small cell lung cancer cells, Seiji Doi; Hiroshi Soda; Mikio Oka; Junji Tsurutani; Takeshi Kitazaki; Yoichi Nakamura; Minoru Fukuda; Yasuaki Yamada; Shimeru Kamihira; Shigeru Kohno, Molecular Cancer Therapeutics, 3(11):1397 - 1402, Nov. 2004, Peer-reviewed
  • Preferential Inhibition of Akt and Killing of Akt-Dependent Cancer Cells by Rationally Designed Phosphatidylinositol Ether Lipid Analogues, S. Sianna Castillo; John Brognard; Pavel A. Petukhov; Chunyu Zhang; Junji Tsurutani; Courtney A. Granville; Min Li; Michael Jung; Kip A. West; Joell G. Gills; Alan P. Kozikowski; Phillip A. Dennis, Cancer Research, 64(8):2782 - 2792, Apr. 2004, Peer-reviewed
  • Reversal of breast cancer resistance protein (BCRP/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibiotic, Ken Shiozawa; Mikio Okai; Hiroshi Soda; Megumi Yoshikawa; Yoji Ikegami; Junji Tsurutani; Katsumi Nakatomi; Yoichi Nakamura; Seiji Doi; Takeshi Kitazaki; Yohei Mizuta; Kunihiko Murase; Hisahiro Yoshida; Douglas D. Ross; Shigeru Kohno, International Journal of Cancer, 108(1):146 - 151, Jan. 2004, Peer-reviewed
  • Autoimmunity to heat shock protein 40 in ulcerative colitis, S. Sato; M. Oka; Y. Noguchi; H. Soda; J. Tsurutani; Y. Nakamura; T. Kitazaki; Y. Mizuta; F. Takeshima; K. Murase; I. Murata; K. Ohtsuka; S. Kohno, Journal of International Medical Research, 32(2):141 - 148, 2004, Peer-reviewed
  • Plasma Thrombopoietin Levels are Unlikely to Account for the Platelet-sparing Effect of Paclitaxel in Lung Cancer Patients, Takashi Kasai; Hiroshi Soda; Mikio Oka; Yoichi Nakamura; Junji Tsurutani; Seiji Nagashima; Minoru Fukuda; Hiroshi Takatani; Masaaki Fukuda; Akitoshi Kinoshita; Tetsuro Kanda; Shigeru Kohno, Acta Medica Nagasakiensia, 48(3-4):101 - 105, Dec. 2003, Peer-reviewed
  • Expression and functional analyses of breast cancer resistance protein in lung cancer, Shigeru Kawabata; Mikio Oka; Hiroshi Soda; Ken Shiozawa; Katsumi Nakatomi; Junji Tsurutani; Yoichi Nakamura; Seiji Doi; Takeshi Kitazaki; Kazuyuki Sugahara; Yasuaki Yamada; Shimeru Kamihira; Shigeru Kohno, Clinical Cancer Research, 9(8):3052 - 3057, Aug. 2003, Peer-reviewed
  • Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors, Roberto Bianco; Incheol Shin; Christoph A. Ritter; F. Michael Yakes; Andrea Basso; Neal Rosen; Junji Tsurutani; Phillip A. Dennis; Gordon B. Mills; Carlos L. Arteaga, Oncogene, 22(18):2812 - 2822, May 2003, Peer-reviewed
  • Antiproliferative effects of the histone deacetylase inhibitor FR901228 on small-cell lung cancer lines and drug-resistant sublines, Junji Tsurutani; Hiroshi Soda; Mikio Oka; Mitsuhiro Suenaga; Seiji Doi; Yoichi Nakamura; Katsumi Nakatomi; Ken Shiozawa; Yasuaki Yamada; Shimeru Kamihira; Shigeru Kohno, International Journal of Cancer, 104(2):238 - 242, Mar. 2003, Peer-reviewed
  • Phase I study of irinotecan and cisplatin with concurrent split-course radiotherapy in limited-disease small-cell lung cancer, M. Oka; M. Fukuda; M. Kuba; M. Ichiki; T. Rikimaru; H. Soda; J. Tsurutani; Y. Nakamura; S. Kawabata; K. Nakatomi; F. Narasaki; S. Nagashima; H. Takatani; M. Fukuda; A. Kinoshita; S. Kohno, European Journal of Cancer, 38(15):1998 - 2004, Oct. 2002, Peer-reviewed
  • Phase I and pharmacokinetic study of paclitaxel and irinotecan for patients with advanced non-small cell lung cancer, T. Kasai; M. Oka; H. Soda; J. Tsurutani; M. Fukuda; Y. Nakamura; S. Kawabata; K. Nakatomi; S. Nagashima; H. Takatani; M. Fukuda; A. Kinoshita; S. Kohno, European Journal of Cancer, 38(14):1871 - 1878, Sep. 2002, Peer-reviewed
  • Mutational analysis of the β-tubulin gene in lung cancer, Junji Tsurutani; Takefumi Komiya; Hisao Uejima; Hirohito Tada; Negoro Syunichi; Mikio Oka; Shigeru Kohno; Masahiro Fukuoka; Kazuhiko Nakagawa, Lung Cancer, 35(1):11 - 16, 2002, Peer-reviewed
  • Point mutations in the topoisomerase I gene in patients with non-small cell lung cancer treated with irinotecan, Junji Tsurutani; Takashi Nitta; Tomonori Hirashima; Takefumi Komiya; Hisao Uejima; Hirohito Tada; Negoro Syunichi; Aritomo Tohda; Masahiro Fukuoka; Kazuhiko Nakagawa, Lung Cancer, 35(3):299 - 304, 2002, Peer-reviewed
  • Phase I study of second-line chemotherapy with docetaxel and carboplatin in advanced non-small-cell lung cancer, M Oka; M Fukuda; S Nagashima; M Fukuda; A Kinoshita; H Soda; S Doi; F Narasaki; M Suenaga; H Takatani; Y Nakamura; S Kawabata; J Tsurutani; T Kanda; S Kohno, CANCER CHEMOTHERAPY AND PHARMACOLOGY, 48(6):446 - 450, Dec. 2001, Peer-reviewed
  • A case of multidrug-resistant pulmonary tuberculosis, J. Tsurutani; H. Sohda; M. Oka; S. Kohno, Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society, 38(8):594 - 598, Aug. 2000, Peer-reviewed
  • A Case of Multidrug-resistant Pulmonary Tuberculosis., 鶴谷純司; 早田宏; 岡三喜男; 河野茂, 日本呼吸器学会雑誌, 38(8):594 - 598, Aug. 2000
  • Phase I study of irinotecan combined with carboplatin in previously untreated solid cancers, Minoru Fukuda; Mikio Oka; Hiroshi Soda; Kenji Terashi; Shigeru Kawabata; Katsumi Nakatomi; Hiroshi Takatani; Junji Tsurutani; Kazuhiro Tsukamoto; Yuji Noguchi; Masaaki Fukuda; Akitoshi Kinoshita; Shigeru Kohno, Clinical Cancer Research, 5(12):3963 - 3969, Dec. 1999, Peer-reviewed
  • A case of pulmonary actinomycosis marked by diagnostic difficulty, J. Tsurutani; M. Tominaga; T. Furukawa; M. Fukuda; H. Soda; M. Oka; S. Kohno, Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society, 37(11):934 - 937, Nov. 1999
  • Bronchoscopic therapy for mucosa-associated lymphoid tissue lymphoma of the trachea, Junji Tsurutani; Akitoshi Kinoshita; Hideyuki Kaida; Hideharu Fujii; Fumihiko Narasaki; Minoru Fukuda; Mikio Oka; Shigeru Kohno, Internal Medicine, 38(3):276 - 278, Mar. 1999
  • A case of drug-induced pneumonitis probably due to irinotecan hydrochloride, Junji Tsurutani; Minoru Fukuda; Masaaki Fukuda; Hiroshi Takatani; Mikio Oka; Shigeru Kohno, Japanese Journal of Lung Cancer, 39(1):57 - 61, Feb. 1999
  • 気管支鏡下エタノール局注が奏効した食道癌気管浸潤による気道狭窄の1例, 木下 明敏; 鶴谷 純司; 佐伯 幸子; 辻 博治; 仲地 厚; 古川 正人; 神崎 修一; 天本 祐平; 荒木 潤; 岡 三喜男; 河野 茂, 国立長崎中央病院医学雑誌, 1(1):44 - 47, Mar. 1998
  • Evaluation of Bronchoalveolar Lavage as a Diagnostic Procedure for Primary Pulmonary B-cell Lymphoma, Reiji NAKANO; Mikio OKA; Masami WATANABE [etc.], Acta medica Nagasakiensia, 43(3):62 - 66, 1998, Peer-reviewed
  • Enhanced expression of metallothionein in human non-small-cell lung carcinomas following chemotherapy, Yoshiyuki Matsumoto; Mikio Oka; Akira Sakamoto; Fumihiko Narasaki; Minoru Fukuda; Hiroshi Takatani; Kenji Terashi; Koki Ikeda; Junji Tsurutani; Seiji Nagashima; Hiroshi Soda; Shigeru Kohno, Anticancer Research, 17(5 B):3777 - 3780, Sep. 1997, Peer-reviewed
  • P-glycoprotein is positively correlated with p53 protein accumulation in human colorectal cancers, Mikio Oka; Kiyoshi Kounoura; Fumihiko Narasaki; Akira Sakamoto; Minoru Fukuda; Isao Matsuo; Koki Ikeda; Junji Tsurutani; Nobuhiro Ikuno; Katsuhisa Omagari; Yohei Mizuta; Hiroshi Soda; Jean M. Gudas; Shigeru Kohno, Japanese Journal of Cancer Research, 88(8):738 - 742, Aug. 1997, Peer-reviewed
  • Bronchial Artery Aneurysm as a Cause of Atelectasis, Mikio Oka; Minoru Fukuda; Kenji Terashi; Hiroshi Takatani; Fumihiko Narasaki; Reiji Nakano; Junji Tsurutani; Yo Ichi Nakamura; Takashi Kasai; Seiji Nagashima; Yuji Noguchi; Hiroshi Soda; Shigeru Kohno, Internal Medicine, 36(12):917 - 919, 1997

Presentations

  • Dato-DXd vs chemotherapy for patients with inoperable/metastatic HR+/HER2– breast cancer: TROPION-Breast01 Asian subset, Junji Tsurutani, Masaya Hattori, Seock-Ah Im, Shusen Wang, Yen-Shen Lu, Joohyuk Sohn, Qingyuan Zhang, Yeon Hee Park, Keun Seok Lee, Yukinori Ozaki, Zefei Jiang, Wei-Pang Chung, Michelino De Laurentiis, Sonia Pernas, Lu Xu, ​ Sabrina Khan, Neelima Denduluri, Barbara Pistilli, Aditya Bardia, Binghe Xu, JSMO, Feb. 2024
  • Toxicity of combination therapy with nivolumab and abemaciclib in HR-positive metastatic breast cancer: WJOG11418B​, Hitomi Sakai, Jun Masuda, Junji Tsurutani, Yuko Tanabe, Norikazu Masuda, Tsutomu Iwasa, Masato Takahashi, Manabu Futamura, Koji Matsumoto, Kenjiro Aogi, Hiroji Iwata, Mari Hosonaga, Toru Mukohara, Kiyoshi Yoshimura, Chiyo K Imamura, Sakiko Miura, Toshiko Yamochi, Hidetaka Kawabata, Hiroyuki Yasojima, Nobumoto Tomioka, Kenichi Yoshimura, Toshimi Takano, JSMO, Feb. 2024
  • Post-T-DXd treatment in patients with ​ HER2-positive metastatic breast cancer: ​ A multicenter cohort study (EN-SEMBLE)​, Kazuki Nozawa, Hiroji Iwata, Toru Mukohara, Tetsuhiko Taira, Kenichi Inoue, Jun Hashimoto, Kazuo Matsuura, Toshiro Mizuno, Yoshiaki Shinden, Mitsugu Yamamoto, Saori Kawai, Makoto Wakahara, Hirofumi Terakawa, Takashi Yamanaka, Yasuyuki Kojima, Fumie Fujisawa, Yuji Hirakawa, Tomoaki Okutsu, Kiyoka Kuge, Junji Tsurutani, JSMO, Feb. 2024
  • Soluble CD163 may be a predictive biomarker of the efficacy of nivolumab plus chemotherapy ​ in patients with HER2-negative metastatic breast cancer (WJOG9917BTR)​, Toru Mukohara, Yukinori Ozaki, Shigehisa Kitano, Makiko Yamashita, Daiki Ikarashi, Junji Tsurutani, Tsutomu Iwasa, Masato Takahashi, ​ Norikazu Masuda, Manabu Futamura, Hironobu Minami, Koji Matsumoto, Yuko Tanabe, Hidetaka Kawabata, Kenichi Yoshimura, Toshimi Takano, SABCS, Dec. 2023
  • Real-world experience with trastuzumab deruxtecan in patients with breast cancer: 6 month-interim analysis of an all-patient postmarketing surveillance in Japan, Junji Tsurutani, Hideki Mizutani, Ayumi Tanabe, SABCS, Dec. 2023
  • Trastuzumab deruxtecan for the treatment of patients with HER2-positive breast cancer with brain and/or leptomeningeal metastases: an updated overall survival analysis using data from a multicenter retrospective study (ROSET-BM study), Takashi Yamanaka, Naoki Niikura, Takahiro Nakayama, Mitsugu Yamamoto, Kazuo Matsuura, Kenichi Inoue, Sachiko Takahara, Hironori Nomura, Shosuke Kita, Miki Yamaguchi, Tomoyuki Aruga, Nobuhiro Shibata, Akihiko Shimomura, Yuri Ozaki, Shuji Sakai, Daisuke Takiguchi, Takehiko Takata, Armin Bastanfard, Kazuhito Shiosakai, Junji Tsurutani, SABCS, Dec. 2023
  • Trastuzumab Deruxtecan (T-DXd) Versus Treatment of Physician’s Choice (TPC) in Patients With HER2-Low Unresectable and/or Metastatic Breast Cancer: Updated Survival Results of the Randomized, Phase 3 ​ DESTINY-Breast04 Study​, Shanu Modi,a William Jacot, Hiroji Iwata, Yeon Hee Park, Maria Jesus Vidal Losada, Wei Li, Junji Tsurutani, Khalil Zaman, Naoto Ueno, Aleix Prat, Konstantinos Papazisis, Hope S. Rugo, Nadia Harbeck, Seock-Ah Im, Michelino De Laurentis, ​ Cecilia Orbegoso Aguilar, Lotus Yung, Fu-Chih Cheng, ​ Yingkai Cheng, David Cameron​, ESMO, Oct. 2023
  • Datopotamab deruxtecan (Dato-DXd) vs chemotherapy in previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2–) breast cancer: ​ Primary results from the randomised ​ Phase 3 TROPION-Breast01 trial, Aditya Bardia, Komal Jhaveri, Seock-Ah Im, Sonia Pernas, ​ Michelino De Laurentiis, Shusen Wang, Noelia Martínez Jañez, ​ Giuliano Borges, David W. Cescon, Masaya Hattori, Yen-Shen Lu, ​ Erika Hamilton, Qingyuan Zhang, Junji Tsurutani, Kevin Kalinsky,​ Lu Xu, Neelima Denduluri, Hope S. Rugo, Binghe Xu, Barbara Pistilli, ESMO, Oct. 2023
  • COMT遺伝子型バイオマーカーを用いたがん性疼痛に対するモルヒネとオキシコドンの比較　無作為化臨床試験, 阪本 亮;松岡 弘道;鶴谷 純司;千葉 康敬;藤田 至彦;酒井 清裕;吉田 健史;名倉 美樹;大武 陽一;小山 敦子;西尾 和人;中川 和彦, 日本心身医学会総会ならびに学術講演会プログラム・抄録集, Jun. 2023
  • Trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC) in patients (pts) with HER2-low, hormone receptor-positive (HR+) unresectable and/or metastatic breast cancer (mBC): exploratory biomarker analysis of DESTINY-Breast04, Shanu Modi, Naoki Niikura, Toshinari Yamashita, William Jacot, Joo Hyuk Sohn, Eriko Tokunaga, Maria Vidal, Yeon Hee Park, Keun Seok Lee, Yee Soo Chae, Naoto Ueno, Aleix Prat, Fumitaka Suto, Yusuke Kuwahara, Robert McEwen, Wenqin Feng, Hiroki Goto, Cecilia Orbegoso Aguilar, David Cameron, Junji Tsurutani, ASCO, Jun. 2023
  • HER2CLIMB-05: Phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+ metastatic breast cancer (trial in progress) , Erika Hamilton, Miguel Martín, Ciara C. O’Sullivan, Giuseppe Curigliano, Joohyuk Sohn, Junji Tsurutani, Konstantinos Tryfonidis, Libero Santarpia, Shan Yang, Veronique Dieras , ASCO, Jun. 2023
  • 実臨床下における浸潤性小葉癌の予後​ 及びエリブリンの有効性の検討, 田辺 裕子, 井上 賢一, 高橋 將人, 向井 博文, 山中 隆司, 柄川 千代美, 内田 洋平, 東別府 洋一, 阪田 幸則, 鶴谷 純司, 第31回日本乳癌学会学術総会, Jun. 2023
  • 再発乳癌とstage IV乳癌における免疫状態および免疫チェックポイント阻害薬に対する反応性の違い: WJOG9917BTR, 尾崎 由記範、北野 滋久、山下 万貴子、五十嵐 大樹、鶴谷 純司、岩朝 勤、高橋 將人、向原 徹, 増田 慎三、二村 学、南 博信、松本 光史、田辺 裕子、川端 英孝、吉村 健一、高野 利実, 第31回日本乳癌学会学術総会, Jun. 2023
  • Trastuzumab deruxtecan for HER2-positive breast cancer with brain and/or leptomeningeal metastases, Nomura Hironori, Naoki Niikura, Takashi Yamanaka, Hiroki Kusama, Mitsugu Yamamoto, Kazuo Matsuura, Kenichi Inoue, Sachiko Takahara, Shousuke Kita, Miki Yamaguchi, Tomoyuki Aruga, Shibata Nobuhiro, Akihiko Shimomura, Yuri Ozaki, Kazuhiro Shiraishi, Shuji Sakai, Tadahiro Izutani, Kazuhito Shiosakai, Mitsuhisa Takatsuki, Junji Tsurutani, 第31回日本乳癌学会学術総会, Jun. 2023
  • DESTINY-Breast04 subgroup analyses of trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC) in patients (pts) with human epidermal growth factor 2 (HER2)-low, estrogen-receptor (ER) expression immunohistochemistry (IHC) 0-10% metastatic breast cancer (mBC), David A. Cameron, William Jacot, Toshinari Yamashita, Maria Vidal, Peter Schmid, Keun Seok Lee, Michelino De Laurentiis, Flora Zagouri, Naoto Ueno, Aleix Prat, Nadia Harbeck, Rinat Yerushalmi, Yen-Shen Lu, Andrea Gombos, Cecilia Orbegoso Aguilar, Fu-Chih Cheng, Lotus Yung, Rachana Rajagopalan,Junji Tsurutani, Shanu Modi, ESMO Breast, May 2023
  • T-DXd vs TPC in patients with HER2-low unresectable and/or metastatic BC in Asian subgroup: results of DESTINY-Breast04, Junji Tsurutani, Shanu Modi, Joo Hyuk Sohn, Eriko Tokunaga, Naoki Niikura, Yeon Hee Park, Keun Seok Lee, Yee Soo Chae, Xiaojia Wang, Wei Li, Seock-Ah Im, Binghe Xu, Yen-Shen Lu, Dhiraj Gambhire, Soichiro Nishijima, Yuji Nishiyama, Masahiro Sugihara, Toshinari Yamashita, JSMO, Feb. 2023
  • 肺腺癌細胞PC-9におけるオシメルチニブの獲得耐性機序の検討, 山岡 利光;長谷部 友紀;眞鍋 亮;岸野 康成;楠本 壮二郎;安藤 浩一;大森 亨;相良 博典;鶴谷 純司, 肺癌, Nov. 2022
  • HER2低発現転移性乳癌を対象としてT-DXdと医師選択治療を比較する第3相試験, 鶴谷 純司;Modi Shanu;Jacot William;山下 年成;Sohn Joo Hyuk;Vidal Maria;徳永 えり子;上野 直人;新倉 直樹;Gambhire Dhiraj;Harbeck Nadia;Cameron David, 日本癌治療学会学術集会抄録集, Oct. 2022
  • 肺腺癌細胞における第3世代EGFR-TKIオシメルチニブの獲得耐性機序の検討(Resistance mechanisms against osimertinib in lung adenocarcinoma cells with EGFR-activating mutation), 西原 成俊;山岡 利光;長谷部 友紀;石川 文博;楠本 壮二郎;大森 亨;相良 博典;吉田 仁;鶴谷 純司, 日本癌学会総会記事, Sep. 2022
  • がん疼痛に対するオピオイド選択のための多型バイオマーカーの探索, 藤田 至彦; 松岡 弘道; 鶴谷 純司; 千葉 康敬; 酒井 清裕; 吉田 健史; 大武 陽一; 小山 敦子; 西尾 和人; 中川 和彦, 日本緩和医療学会, Jul. 2022
  • アベマシクリブ関連薬剤性肺障害のネステッドケースコントロール研究, 中山 紗由香;吉沢 あゆは;鶴谷 純司;吉村 健一;長瀬 洋之;細永 真理;小島 康幸;平 成人;相原 智彦;木川 雄一郎;向井 博文, 日本乳癌学会総会プログラム抄録集, Jun. 2022
  • HER2+ mBC患者を対象としたT-DXd投与中のCINVに対するオランザピン投与の第II相試験　WJOG14320B(ERICA)(Phase II study of olanzapine for CINV during T-DXd in HER2+ mBC patients: WJOG14320B(ERICA)), 酒井 瞳;鶴谷 純司;横江 隆道;今村 知世;松本 光史;岩朝 勤;千葉 康敬;平川 雄士;高野 利実, 日本乳癌学会総会プログラム抄録集, Jun. 2022
  • ハンドセラピー施術と冷却法の併用によるCIPNのしびれ改善方法, 佐々木 晶子;垂野 香苗;鶴谷 純司;池田 明子;中村 清吾, 日本乳癌学会総会プログラム抄録集, Jun. 2022
  • ペグフィルグラスチム投与用の新規医療デバイスの評価(Evaluation of a novel medical device for pegfilgrastim administration), Aruga Tomoyuki;Doihara Hiroyoshi;Yanagita Yasuhiro;Ishida Takanori;Yamashita Toshinari;Uehara Kanou;Taira Tetsuhiko;Tsurutani Junji;Takeshita Takashi;Tsuyuki Shigeru;Kaneko Koji;Ohtake Tohru;Yamaguchi Yusuke;Hara Yui;Saji Shigehira, Cancer Science, May 2022
  • EGFR遺伝子変異を有する肺腺癌細胞PC-9における第３世代EGFR-TKI, オシメルチニブの獲得耐性機序の検討, 山岡　利光;岸野　康成;楠本　壮二郎;安藤　浩一;大森　亨;相良　博典;鶴谷　純司, 第62回日本肺癌学会学術集会, 27 Nov. 2021, 横浜・LIVE配信・オンデマンド配信
  • ハンドセラピー施術と冷却法の併用によるCIPNのしびれ改善方法, 佐々木　晶子;垂野　香苗;鶴谷　純司;和泉　麻里子;木内　祐二;中村　清吾, 第59回日本癌治療学会学術集会, 21 Oct. 2021, 現地(横浜) ＋ Live配信
  • Mechanism of resistance to third-generation EGFR-TKI, osimertinib, in lung adenocarcinoma PC-9 cells, 山岡　利光;岸野　康成;楠本　壮二郎;安藤　浩一;大森　亨;相良　博典;鶴谷　純司, 第80回⽇本癌学会学術総会, 02 Oct. 2021, 横浜
  • Stage II膵臓癌における予後因子としての好酸球数、好酸球リンパ球比に関する検討, 大熊 遼太朗;久保田 祐太郎;堀池 篤;鶴井 敏光;鈴木 理沙子;入口 菜々;石黒 智之;平澤 優弥;有泉 裕嗣;家口 勝昭;高柳 大輔;鶴谷 純司;吉村 清;角田 卓也;和田 聡, 日本癌治療学会学術集会抄録集, Oct. 2021
  • 抗PD-1抗体で発症せず、抗PD-L1抗体投与後に血球貪食症候群様の免疫関連有害事象を発症した肺癌症例, 有泉　裕嗣;吉村　清;堀池　篤;平澤　優弥;石黒　智之;大熊　遼太朗;久保田　祐太郎;濵田　和幸;和田　聡;鶴谷　純司;角田　卓也, 第25回日本がん免疫学会総会, 03 Jul. 2021, 和歌山
  • A case of primary lung cancer that led to the diagnosis of SMARCA4-deficient thoracic sarcoid tumor by oncogene panel testing, Nana Iriguchi; Atsushi Horiike; Tomoyuki Ishiguro; Ryotaro Ohkuma; Shigetoshi Nishihara; Satoshi Matsukuma; Hirotsugu Ariizumi; Reiko Yoshida; Yutaro Kubota; Ryosuke Hanaoka; Satoshi Wada; Junji Tsurutani; Kiyoshi Yoshimura; Toshiko Yamochi; Kengo Takeuchi; Shunji Takahashi; Seigo Nakamura; Takuya Tsunoda, JSMO, Jul. 2021
  • アベマシクリブ関連薬剤性肺障害のネステッドケースコントロース研究, 吉沢 あゆは;中山 紗由香;鶴谷 純司;吉村 健一;細永 真理;中山 貴寛;平 成人;石川 孝;遠山 竜也;木川 雄一郎;向井 博文, 日本乳癌学会総会プログラム抄録集, Jul. 2021
  • がん疼痛に対するオピオイド選択のためのバイオマーカーを用いたランダム化比較試験(Relief Study), 松岡 弘道; 鶴谷 純司; 千葉 康敬; 藤田 至彦; 酒井 清裕; 吉田 健史; 大武 陽一; 名倉 美樹; 小山 敦子; 西尾 和人; 中川 和彦, 日本緩和医療学会, Jun. 2021
  • A case report on severe nivolumab-induced adverse events similar to primary sclerosing cholangitis refractory to immunosuppressive therapy., Yuya Hirasawa; Kiyoshi Yoshimura; Hiroto Matsui; Yutaro Kubota; Hiroo Ishida; Jun Arai; Masashi Sakaki; Nao Oguro; Midori Shida; Makoto Taniguchi; Kazuyuki Hamada; Hirotsugu Ariizumi; Tomoyuki Ishiguro; Ryotaro Ohkuma; Takehiko Sambe; Atsushi Horiike; Chiyo K Imamura; Eisuke Shiozawa; Satoshi Wada; Junji Tsurutani; Sanju Iwamoto; Naoki Uchida; Yuji Kiuchi; Genshu Tate; Shinichi Kobayashi; Takuya Tsunoda, Medicine, Jun. 2021
  • Atezolizumab投与後の免疫関連有害事象により重症筋無力症と完全房室ブロックを発症した一例, 入口 菜々;堀池 篤;大熊 遼太朗;石黒 智之;有泉 祐嗣;久保田 祐太郎;石崎 秀信;花岡 亮輔;和田 聡;鶴谷 純司;吉村 清;角田 卓也, 日本がん免疫学会総会プログラム・抄録集, May 2021
  • 免疫チェックポイント阻害薬の受容体占拠率と有効性・有害事象との関連, 細沼 雅弘;平澤 優弥;成川 陽一郎;村山 正和;志田 みどり;有泉 裕嗣;石黒 智之;大熊 遼太朗;久保田 祐太郎;堀池 篤;和田 聡;鶴谷 純司;小林 真一;倉増 敦朗;角田 卓也;吉村 清, 日本がん免疫学会総会プログラム・抄録集, May 2021
  • 切除不能進行・再発胃がんにおけるニボルマブ療法によるsuper hyper progressive diseaseの検討, 久保田 祐太郎;吉村 清;濱田 和幸;平澤 優弥;志田 みどり;谷口 誠;松井 洋人;有泉 裕嗣;石黒 智之;大熊 遼太朗;三邊 武彦;石田 博雄;堀池 篤;和田 聡;鶴谷 純司;巖本 三壽;内田 直樹;木内 祐二;小林 真一;角田 卓也, 日本がん免疫学会総会プログラム・抄録集, May 2021
  • 抗PD-1抗体で発症せず、抗PD-L1抗体投与後に血球貪食症候群様の免疫関連有害事象を発症した肺癌症例, 有泉 裕嗣;吉村 清;堀池 篤;平澤 優弥;石黒 智之;大熊 遼太朗;久保田 祐太郎;濱田 和幸;和田 聡;鶴谷 純司;角田 卓也, 日本がん免疫学会総会プログラム・抄録集, May 2021
  • 高齢がん患者における抗腫瘍効果に関与する免疫学的因子の検討, 平澤 優弥;尾上 りえ;志田 みどり;細沼 雅弘;石黒 智之;大熊 遼太朗;有泉 裕嗣;久保田 祐太郎;濱田 和幸;倉増 敦朗;谷口 誠;三邉 武彦;堀池 篤;和田 聡;鶴谷 純司;角田 卓也;吉村 清, 日本がん免疫学会総会プログラム・抄録集, May 2021
  • 腸内細菌を介したがん免疫微小環境へのアプローチ, 吉村 清;細沼 雅弘;濱田 和幸;平澤 優弥;志田 みどり;成川 陽一郎;村山 正和;石黒 智之;大熊 遼太朗;有泉 裕嗣;久保田 祐太郎;堀池 篤;和田 聡;鶴谷 純司;倉増 敦朗;角田 卓也, 日本外科学会定期学術集会抄録集, Apr. 2021
  • Immunological analysis of the combination therapy of nivolumab, paclitaxel and bevacizumab in patients with HER2negative MBC in NEWBEAT trial (WJOG9917BTR), Yukinori Ozaki; Shigehisa Kitano; Junji Tsurutani; Tsutomu Iwasa; Masato Takahashi; Toru Mukohara; Norikazu Masuda; Manabu Futamura; Hironobu Minami; Koji Matsumoto; Hidetaka Kawabata; Makiko Yamashita; Kenichi Yoshimura; Toshimi Takano, SABCS, Feb. 2021
  • Phase II study of nivolumab in combination with abemaciclib plus endocrine therapy in patients with HR+, HER2-metastatic breast cancer: WJOG11418B NEWFLAME trial, Jun Masuda; Junji Tsurutani; Norikazu Masuda; Yuko Tanabe; Tsutomu Iwasa; Masato Takahashi; Manabu Futamura; Koji Matsumoto; Kenjiro Aogi; Hiroji Iwata; Mari Hosonaga; Toru Mukohara; Kenichi Yoshimura; Toshimi Takano, SABCS, Feb. 2021
  • Updated results from DESTINY-breast01, a phase 2 trial of trastuzumab deruxtecan (T-DXd) in HER2 positive metastatic breast cancer, Shanu Modi; Cristina Saura; Toshinari Yamashita; Yeon Hee Park; Sung-Bae Kim; Kenji Tamura; Fabrice Andre; Hiroji Iwata; Yoshinori Ito; Junji Tsurutani; Joohyuk Sohn; Neelima Denduluri; Christophe Perrin; Kenjiro Aogi; Eriko Tokunaga; Seock-Ah Im; Keun Seok Lee; Sara A. Hurvitz; Javier Cortes; Caleb Lee; Yali Liu; Lin Zhang; Javad Shahidi; Antoine Yver; Jose Baselga; Ian E. Krop, SABCS, Feb. 2021
  • High expression of human epididymis protein 4 correlates with chemoresistance and poor prognosis for pancreatic cancer, Ryotaro Ohkuma; Erica Yada; Shumpei Ishikawa; Daisuke Komura; Yutaro Kubota; Kazuyuki Hamada; Atsushi Horiike; Kiyohiro Ando; Junji Tsurutani; Kiyoshi Yoshimura; Tetsuro Sasada; Masahiko Murakami; Masafumi Takimoto; Takuya Tsunoda; Satoshi Wada, CANCER SCIENCE, Feb. 2021
  • Randomized phase II study to determine the optimal dose of 3-week cycle nab-paclitaxel in patients with metastatic breast cancer., Tsurutani Junji;Hara Fumikata;Kitada Masahiro;Takahashi Masato;Kikawa Yuichiro;Kato Hiroaki;Sakata Eiko;Naito Yoichi;Hasegawa Yoshie;Saito Tsuyoshi;Iwasa Tsutomu;Taira Naruto;Takashima Tsutomu;Kashiwabara Kosuke;Aihara Tomohiko;Mukai Hirofumi, Breast (Edinburgh, Scotland), Dec. 2020
  • HER2-Targeted Therapies in HER2-Low-Expressing Breast Cancer Reply, Shanu Modi; Haeseong Park; Rashmi K. Murthy; Hiroji Iwata; Kenji Tamura; Junji Tsurutani; Alvaro Moreno-Aspitia; Toshihiko Doi; Yasuaki Sagara; Charles Redfern; Ian E. Krop; Caleb Lee; Yoshihiko Fujisaki; Masahiro Sugihara; Lin Zhang; Javad Shahidi; Shunji Takahashi, ASCO, Oct. 2020
  • Human epididymis protein 4の発現が膵臓癌における抗癌剤耐性・予後不良に与える影響, 大熊 遼太朗;矢田 英理香;石川 俊平;河村 大輔;久保田 祐太郎;濱田 和幸;堀池 篤;安藤 清宏;鶴谷 純司;吉村 清;笹田 哲朗;村上 雅彦;瀧本 雅文;角田 卓也;和田 聡, 日本癌学会総会記事, Oct. 2020
  • HER2低発現の転移性乳癌におけるtrastuzumab deruxtecan(T-DXd、DS-8201)と治験担当医師が選択した化学療法の比較に関する第3相試験(A phase 3 trial of trastuzumab deruxtecan(T-DXd;DS-8201) vs chemotherapy of investigator's choice in HER2-low metastatic breast cancer), Tsurutani Junji;Ohtani Shoichiro;Takano Toshimi;Modi Shanu;Cameron David;Lee Caleb;Wang Yibin;Saxena Kapil;Saito Kaku;Nishijima Soichiro;Iwata Hiroji, 日本乳癌学会総会プログラム抄録集, Oct. 2020
  • エリブリンの第3相臨床試験および製造販売後調査における効果予測因子の解析, 三好 康雄;渡邉 純一郎;吉村 祐太;齋藤 健一;村本 賢三;阪田 幸則;野本 研一;井上 賢一;向井 博文;鶴谷 純司;高橋 將人, 日本乳癌学会総会プログラム抄録集, Oct. 2020
  • HER2陽性進行乳癌患者を対象としたDS-8201のfirst-inhuman第1相試験及び第2相試験(DESTINY-Breast01)における併合解析及び日本人サブセット解析, 田村 研治;鶴谷 純司;岩田 広治;高橋 俊二;Krop Ian;Saura Cristina;山下 年成;相良 安昭;杉原 匡周;神尾 恭弘;藤崎 良彦;齊藤 格;Modi Shanu, 日本乳癌学会総会プログラム抄録集, Oct. 2020
  • 転移再発乳癌におけるパクリタキセル+ベバシズマブ導入化学療法後のホルモン療法+カペシタビン併用維持療法, 池田 雅彦;中山 貴寛;吉波 哲大;水谷 麻紀子;山口 美樹;菰池 佳史;高島 勉;吉留 克英;鶴谷 純司;岩本 充彦;藤澤 文絵;八十島 宏行;山村 順;山田 知美;増田 慎三, 日本乳癌学会総会プログラム抄録集, Oct. 2020
  • HER2陰性転移性乳癌患者に対する一次治療としてのニボルマブ+パクリタキセル+ベバシズマブ併用療法の有効性を評価する多施設第II相試験　WJOG9917B NEWBEAT試験(A multicenter Phase II study evaluating the efficacy of nivolumab plus paclitaxel plus bevacizumab triple-combination therapy as a first-line treatment in patients with HER2-negative metastatic breast cancer: WJOG9917B NEWBEAT trial), Ozaki Yukinori;Mukohara Toru;Tsurutani Junji;Takahashi Masato;Matsumoto Koji;Futamura Manabu;Masuda Norikazu;Kitano Shigehisa;Yoshimura Kenichi;Minami Hironobu;Takano Toshimi, 日本乳癌学会総会プログラム抄録集, Oct. 2020
  • EGFRチロシンキナーゼ阻害剤によるSPC-TNFトランスジェニックマウスにおける肺組織損傷とアポトーシス誘導機序の検討, 山岡　利光;大森　亨;安藤　浩一;楠本　壮二郎;本間　哲也;岸野　康成;眞鍋　亮;相良　博典;鶴谷　純司, 第60回日本呼吸器学会学術講演会, 20 Sep. 2020, Web開催
  • EGFRチロシンキナーゼ阻害剤によるSPC-TNFトランスジェニックマウスにおける肺組織損傷とアポトーシス誘導機序の検討, 山岡 利光;大森 亨;安藤 浩一;楠本 壮二郎;本間 哲也;岸野 康成;眞鍋 亮;相良 博典;鶴谷 純司, 日本呼吸器学会誌, Aug. 2020
  • ペムブロリズマブ投与後、皮膚症状が先行し、乾癬性関節炎を発症した肺扁平上皮癌の1例, 石黒 智之;堀池 篤;石田 博雄;平澤 優弥;大熊 遼太朗;松井 洋人;有泉 裕嗣;久保田 祐太郎;濱田 和幸;和田 聡;鶴谷 純司;吉村 清;角田 卓也, 肺癌, Apr. 2020
  • A multicenter phase II study evaluating the efficacy of nivolumab plus paclitaxel plus bevacizumab triple-combination therapy as a first-line treatment in patients with HER2-negative metastatic breast cancer: WJOG9917B NEWBEAT trial, Yukinori Ozaki; Toru Mukohara; Junji Tsurutani; Masato Takahashi; Koji Matsumoto; Manabu Futamura; Norikazu Masuda; Shigehisa Kitano; Kenichi Yoshimura; Hironobu Minami; Toshimi Takano, SABCS, Feb. 2020
  • Patient-reported outcomes in a randomized, optimal dose finding, phase II study of triweekly nab-paclitaxel in patients with metastatic breast cancer (the ABROAD study), KATO Hiroaki;HARA Fumikata;KITADA Masahiro;TAKAHASHI Masato;KIKAWA Yuichiro;SAKATA Eiko;NAITO Yoichi;HASEGAWA Yoshie;SAITO Tsuyoshi;IWASA Tsutomu;TSURUTANI Junji;TAIRA Naruto;TAKASHIMA Tsutomu;KASHIWABARA Kosuke;AIHARA Tomohiko;MUKAI Hirofumi, San Antonio Breast Cancer Symposium 2019, 12 Dec. 2019, San Antonio
  • Phase II study of trimebutine maleate and probiotics for abemaciclib-induced diarrhea in patients with ER-positive and HER 2-negative advanced breast cancer (MERMAID) WJOG 11318 B, MASUDA Hiroko;IWASA Tsutomu;MUKOHARA Toru;TOKUNAGA Shinya;MATSUMOTO Koji;NIIKURA Naoki;SAGARA Yasuaki;MIYOSHI Yasuo;SHIMOMURA Akihiko;TAKAHASHI Masato;NAGASHIMA Takeshi;DOI Mihoko;FUTAMURA Manabu;YOSHIMURA Kenichi;TAKANO Toshimi;TSURUTANI Junji, San Antonio Breast Cancer Symposium, 12 Dec. 2019, San Antonio
  • Phase II study of nivolumab in combination with abemaciclib plus endocrine therapy in patients with hormone receptor-positive, human epidermal growth factor receptor-2 negative metastatic breast cancer (WJOG 11418 B, NEWFLAME trial), MASUDA Jun;TSURUTANI Junji;MASUDA Norikazu;FUTAMURA Manabu;MATSUMOTO Koji;AOGI Kenjiro;TAKAHASHI Masato;IWATA Hiroji;IWASA Tsutomu;MUKOHARA Toru;YOSHIMURA Kenichi;UENO Takayuki;TAKANO Toshimi, San Antonio Breast Cancer Symposium, 12 Dec. 2019, San Antonio
  • Addition of capecitabine to maintenance endocrine therapy after induction therapy with bevacizumab plus paclitaxel in hormone receptor positive and HER2 negative metastatic breast cancer (KBCSG-TR 1214), YOSHINAMI Tetsuhiro;NAKAYAMA Takahiro;IKEDA Masahiko;MIZUTANI Makiko;YAMAGUCHI Miki;KOMOIKE Yoshifumi;TAKASHIMA Tsutomu;YOSHIDOME Katsuhide;TSURUTANI Junji;IWAMOTO Mitsuhiko;FUJISAWA Fumie;YASOJIMA Hiroyuki;YAMAMURA Jun;MORISHIMA Hirotaka;AKI Fuminori;YAMADA Tomomi;MORITA Satoshi;MASUDA Norikazu, San Antonio Breast Cancer Symposium 2019, 12 Dec. 2019, San Antonio
  • [Fam-] trastuzumab deruxtecan (T-DXd; DS-8201a) in subjects with HER 2-positive metastatic breast cancer previously treated with T-DM 1: A phase 2, multicenter, open-label study （DESTINY-Breast 01, KROP Ian E;SAURA Cristina;YAMASHITA Toshinari;PARK Yeon Hee;KIM Sung-Bae;TAMURA Kenji;ANDRÉ Fabrice;IWATA Hiroji;ITO Yoshinori;TSURUTANI Junji;SOHN Joohyuk;DENDULURI Neelima;PERRIN Christophe;AOGI Kenjiro;TOKUNAGA Eriko;IM Seock-Ah;LEE Keun Seok;HURVITZ Sara;CORTES Javier;LEE Caleb;CHEN Shuquan;ZHANG Lin;SHAHIDI Javad;YVER Antoine;MODI Shanu, San Antonio Breast Cancer Symposium, 11 Dec. 2019, San Antonio
  • Treatment strategy for patients with HER2-negative advanced breast cancer, 鶴谷　純司, 第17回日本乳癌学会近畿地方会, 07 Dec. 2019, 神戸
  • 固形がんにおける早期がん診断法の確立及び治療効果予測バイオマーカーの開発, 和田 聡;濱田 和幸;安藤 清宏;久保田 祐太郎;堀池 篤;有泉 裕嗣;平澤 優弥;大熊 遼太朗;石黒 智之;吉村 清;鶴谷 純司;角田 卓也;小林 真一, 臨床薬理, Nov. 2019
  • ゲフィチニブを用いた化学療法の効果を比較した第III相試験WJTOG3405の全生存期間に関する最終解析(Final overall survival results of WJTOG3405, a phase III trial comparing gefitinib with chemotherapy), Yoshioka Hiroshige;Shimokawa Mototsugu;Seto Takashi;Morita Satoshi;Yatabe Yasushi;Okamoto Isamu;Tsurutani Junji;Satouchi Miyako;Hirashima Tomonori;Atagi Shinji;Shibata Kazuhiko;Saito Hiroshi;Toyooka Shinichi;Yamamoto Nobuyuki;Nakagawa Kazuhiko;Mitsudomi Tetsuya, 肺癌, Nov. 2019
  • A prospective real-world study of eribulin for HER2-negative recurrent breast cancer patients: final results, Hirofumi Mukai; Kenichi Inoue; Masato Takahashi; Takashi Yamanaka; Chiyomi Egawa; Yukinori Sakata; Hiroki Ikezawa; Toshiyuki Matsuoka; Mika Ishii; Junji Tsurutani, JSMO, Oct. 2019
  • Atezolizumab plus nab-paclitaxel as first line therapy in Japanese patients with TNBC: A subgroup analysis of IMpassion130, Kenichi Inoue; Akihiko Shimomura; Koji Kaneko; Yoshinori Ito; Koichiro Tsugawa; Teruo Yamauchi; Junji Tsurutani; Naoki Niikura; Masataka Sawaki; Hiroyoshi Doihara; Yasuo Miyoshi; Ayumi Hasegawa; Shintaro Nakagawa; Hiroyasu Kuratomi; Hiroji Iwata, JSMO, Oct. 2019
  • Dose justification for [fam-] trastuzumab deruxtecan (DS-8201a) in HER2-positive breast cancer, Shunji Takahashi; Shanu Modi; Junji Tsurutani; Ian E. Krop; Hiroji Iwata; Russell Wada; Ophelia Yin; Tushar Garimella; Masahiro Sugihara; Lin Zhang; Caleb Lee; Kaku Saito; Yui Kawasaki; Antoine Yver; Kenji Tamura, JSMO, Oct. 2019
  • 術前化学療法あり、なし乳がん患者における予後因子としてのBRCAness検討(BRCAness As a Prognostic Factor in Breast Cancer Patients With or Without Neoadjuvant Chemotherapy), 松永 有紀;リウ・レイ ;明石 定子;犬塚 真由子;増田 紘子;阿多 亜里沙;山岡 利光;大場 基;中村 清吾;鶴谷 純司, 日本癌学会総会記事, Sep. 2019
  • Blockade of EGFR activation promotes TNF-induced lung epithelial cell apoptosis and pulmonary injury, Toshimitsu Yamaoka; Satoru Arata; Mayumi Homma; Tetsuya Homma; Sojiro Kusumoto; Koichi Ando; Ryou Manabe; Yasunari Kishino; Motoi Ohba; Junji Tsurutani; Masafumi Takimoto; Tohru Ohmori; Hironori Sagara, International Journal of Molecular Sciences, Aug. 2019
  • U3-1402, a HER3-targeting ADC, sensitizes tumors with HER3 expression to PD-1 blockade: A preclinical research, HARATANI Koji;YONESAKA Kimio;TAKAMURA Fuminori;MAENISHI Osamu;KATO Ryoji;TAKEGAWA Naoki;KAWAKAMI Hisato;TANAKA Kaoru;HAYASHI Hidetoshi;TAKEDA Masayuki;MAEDA Naoyuki;AKEMATSU Takashi;HIROTANI Kenji;TSURUTANI Junji;NISHIO Kazuto;MIYAZAWA Masaaki;NAKAGAWA Kazuhiko, 第17回日本臨床腫瘍学会学術集会 (JSMO 2019), 19 Jul. 2019, 京都
  • Phase 3 study of [fam-] trastuzumab deruxtecan (DS-8201a) vs T-DM1 in advanced HER2-positive breast cancer, YAMASHITA Toshinari;VERMA Sunil;CORTES Javier;OTANI Shoichiro;KANEKO Koji;ITO Yoshinori;TAKAHASHI Masato;INOUE Kenichi;IWATA Hiroji;JAVAD Shahidi;LEE Caleb;WANG Kongming;SAITO Kaku;MYOUBATAKE Yusuke;TSURUTANI Junji, 第17回日本臨床腫瘍学会学術集会 (JSMO 2019), 19 Jul. 2019, 京都
  • Updated results of phase 1 study of [fam-] trastuzumab deruxtecan in HER2-expressing or -mutated advanced NSCLC, NAKAGAWA Kazuhiko;DOI Toshihiko;TAKAHASHI Shunji;YOH Kiyotaka;TSURUTANI Junji;PARK Haeseong;MODI Shanu;KROP Ian E.;WAQAR Saiama N.;LI Bob T.;TAIRA Shinichiro;SAITO Kaku;FUJISAKI Yoshihiko;JIKOH Takahiro;SINGH Jasmeet;SUGIHARA Masahiro;PASI A. Janne, 第17回日本臨床腫瘍学会学術集会 (JSMO 2019), 19 Jul. 2019, 京都
  • A phase 2 study evaluating ddAC-ddPTX supported by peg-filgrastim for patients with primary breast cancer -WJOG9016B-, OZAKI Yukinori;MATSUMOTO Koji;NISHIMURA Akiko;FUTAMURA Manabu;MIYAGI Hisako;TSURUTANI Junji;IWASA Tsutomu;IMOTO Hisashi;DOI Mihoko;TOKUNAGA Shinya;AOGI Kenjiro;YOSHIMURA Kenichi;KITAGAWA Koichi;SAGARA Yasuaki;BABA Motoi;NAGAI Shigenori;TAKANO Toshimi, 第17回日本臨床腫瘍学会学術集会 (JSMO 2019), 18 Jul. 2019, 京都
  • Expression of Olfactomedin-4 in pancreatic cancer and its clinical significance, OKUMA Ryotaro;KUBOTA Yutaro;HAMADA Kazuyuki;ISHIDA Hiroo;HIRASAWA Yuya;ARIIZUMI Hirotsugu;SATOH Etsuko;SHIDA Midori;WATANABE Makoto;TSURUTANI Junji;YOSHIMURA Kiyoshi;AOKI Takeshi;MURAKAMI Masahiko;NOROSE Tomoko;OHIKE Nobuyuki;TAKIMOTO Masafumi;TSUNODA Takuya;WADA Satoshi, 第17回日本臨床腫瘍学会学術集会 (JSMO 2019), 18 Jul. 2019, 京都
  • Updated results of [fam-] trastuzumab deruxtecan (DS-8201a) in HER2-low breast cancer from a large phase 1 study, TSURUTANI Junji;MODI Shanu;TAKAHASHI Shunji;PARK Haeseong;IWATA Hiroji;MURTHY Rashmi;SAGARA Yasuaki;KROP Ian E.;DOI Toshihiko;REDFERN Charles;MORENO-ASPITIA Alvaro;REDMAN Rebecca;LEE Caleb;SUGIHARA Masahiro;SAITO Kaku;FUJISAKI Yoshihiko;SATO Yuta;TAMURA Kenji, 第17回日本臨床腫瘍学会学術集会 (JSMO 2019), 18 Jul. 2019, 京都
  • Dose justification for [fam-] trastuzumab deruxtecan (DS-8201a) in HER2-positive breast cancer, TAKAHASHI Shunji;MODI Shanu;TSURUTANI Junji;KROP Ian E.;IWATA Hiroji;WADA Russell;YIN Ophelia;GARIMELLA Tushar;SUGIHARA Masahiro;ZHANG Lin;LEE Caleb;SAITO Kaku;KAWASAKI Yui;YVER Antoine;TAMURA Kenji, 第17回日本臨床腫瘍学会学術集会 (JSMO 2019), 18 Jul. 2019, 京都
  • Exploration of biomarkers for the choice of chemotherapy in colorectal cancer patients, FUJITA Yoshihiko;TAGURI Masataka;YAMAZAKI Kentaro;TSURUTANI Junji;SAKAI Kazuko;BOKU Narikazu;HYODO Ichinosuke;YAMANAKA Takeharu;NISHIO Kazuto, 第17回日本臨床腫瘍学会学術集会 (JSMO 2019), 18 Jul. 2019, 京都
  • Randomized Phase II study of tri-weekly nab-paclitaxel in patients with metastatic breast cancer: ABROAD, TAKAHASHI Masato;HARA Fumikata;KITADA Masahiro;KIKAWA Yuichiro;KATO Hiroaki;SAKATA Hideko;NAITO Yoichi;HASEGAWA Yoshie;SAITO Hiroshi;IWASA Tsutomu;TSURUTANI Junji;TAIRA Naruhito;TAKASHIMA Tsutomu;KASHIWABARA Kosuke;AIHARA Tomohiko;MUKAI Hirofumi, 第17回日本臨床腫瘍学会学術集会 (JSMO 2019), 18 Jul. 2019, 京都
  • Atezolizumab + nab-paclitaxel as first line therapy in Japanese patients with TNBC: A subgroup analysis of IMpassion130, INOUE Kenichi;SHIMOMURA Akihiko;KANEKO Koji;ITO Yoshinori;TSUGAWA Koichiro;YAMAUCHI Teruo;TSURUTANI Junji;NIIKURA Naoki;SAWAKI Masataka;DOIHARA Hiroyoshi;MIYOSHI Yasuo;HASEGAWA Ayumi;NAKAGAWA Shintaro;KURATOMI Hiroyasu;IWATA Hiroji, 第17回日本臨床腫瘍学会学術集会 (JSMO 2019), 18 Jul. 2019, 京都
  • A prospective real-world study of eribulin for HER2-negative recurrent breast cancer patients: final results, MUKAI Hirofumi;INOUE Kenichi;TAKAHASHI Masato;YAMANAKA Takashi;EKAWA Chiyomi;SAKATA Yukinori;IKEZAWA Hiroki;MATSUOKA Toshiyuki;ISHII Mika;TSURUTANI Junji, 第17回日本臨床腫瘍学会学術集会 (JSMO 2019), 18 Jul. 2019, 京都
  • High expression of Olfactomedin-4 correlates with chemoresistance and poor prognosis for pancreatic cancer, Ryotaro Ohkuma; Erica Yada; Yutaro Kubota; Kazuyuki Hamada; Hiroo Ishida; Yuya Hirasawa; Hirotsugu Ariizumi; Etsuko Satoh; Junji Tsurutani; Kiyoshi Yoshimura; Tetsuro Sasada; Takeshi Aoki; Masahiko Murakami; Tomoko Norose; Nobuyuki Ohike; Masafumi Takimoto; Takuya Tsunoda; Satoshi Wada, AACR, Jul. 2019
  • KRAS amplification mediates resistance to osimertinib in acquired afatinib-resistant NSCLC harboring exon 19 deletion/T790M in EGFR, Toshimitsu Yamaoka; Ohba Motoi; Yasunari Kishino; Sojiro Kusumoto; Junji Tsurutani; Tohru Ohmori, AACR, Jul. 2019
  • HER2陽性乳癌患者を対象とした[fam-] trastuzumab deruxtecan(DS-8201a)とT-DM1を比較する第3相臨床試験(A phase 3 study of [fam-] trastuzumab deruxtecan (DS-8201a) vs T-DM1 for subjects with HER2-positive breast cancer), Ohtani Shoichiro;Verma Sunil;Cortes Javier;Kaneko Koji;Tsurutani Junji;Iwata Hiroji;Shahidi Javad;Lee Caleb;Wang Kongming;Saito Kaku;Myobatake Yusuke;Yamashita Toshinari, 日本乳癌学会総会プログラム抄録集, Jul. 2019
  • HER2陽性乳癌細胞株における抗HER3抗体パトリツマブと抗HER2抗体トラスツズマブ/ペルツズマブの3剤併用治療, 渡邉 諭美;鶴谷 純司;広川 恵寿輝;酒井 瞳;岩朝 勤;中川 和彦, 日本乳癌学会総会プログラム抄録集, Jul. 2019
  • HER2陽性乳癌に対する[fam-] trastuzumab deruxtecan(DS-8201a)の投与量最適化(Dose justification for [fam-] trastuzumab deruxtecan (DS-8201a) in HER2-positive breast cancer), Tamura Kenji;Modi Shanu;Tsurutani Junji;Krop Ian;Iwata Hiroji;Baselga Jose;Wada Russell;Yin Ophelia;Garimella Tushar;Sugihara Masahiro;Zhang Lin;Lee Caleb;Saito Kaku;Kawasaki Yui;Yver Antoine;Takahashi Shunji, 日本乳癌学会総会プログラム抄録集, Jul. 2019
  • 日本における新規乳がん治療薬の開発　HER2低発現乳癌に対する[fam-] trastuzumab deruxtecan(DS-8201a)　大規模第1相臨床試験の中間報告([Fam-] trastuzumab deruxtecan (DS-8201a) in HER2-low breast cancer: Updated results of a large phase 1 study), Sagara Yasuaki;Modi Shanu;Tamura Kenji;Takahashi Shunji;Park Haeseong;Iwata Hiroji;Murthy Rashmi;Lee Caleb;Sugihara Masahiro;Saito Kaku;Fujisaki Yoshihiko;Sato Yuta;Tsurutani Junji, 日本乳癌学会総会プログラム抄録集, Jul. 2019
  • KRAS Amplification Mediates Resistance to Osimertinib in Acquired Afatinib-Resistant PC-9 cells Harboring Exon 19 Deletion/T790M in EGFR, 山岡　利光;大森　亨;相良　博典;鶴谷　純司, 第23回日本がん分子標的治療学会学術集会, 13 Jun. 2019, 大阪
  • Randomized, optimal dose-finding, phase II study of tri-weekly nab-paclitaxel in patients with metastatic breast cancer (ABROAD)., Fumikata Hara; Masahiro Kitada; Masato Takahashi; Yuichiro Kikawa; Hiroaki Kato; Eiko Sakata; Yoichi Naito; Yoshie Hasegawa; Tsuyoshi Saito; Tsutomu Iwasa; Junji Tsurutani; Naruto Taira; Tsutomu Takashima; Kosuke Kashiwabara; Tomohiko Aihara; Hirofumi Mukai, ASCO, May 2019
  • Relation between dexamethasone (DEX) usage, preventive trimetprim/sulfametoxazole (ST), and pneumocystis pneumonia (PCP) for patients with breast cancer receiving dose-dense AC followed by dose-dense paclitaxel (ddAC-ddP): Preplanned analysis of WJOG9016B., Koji Matsumoto; Meiko Nishimura; Yukinori Ozaki; Manabu Futamura; Toshikio Miyaki; Junji Tsurutani; Shigeru Imoto; Mihoko Doi; Shinya Tokunaqa; Kenjiro Aogi; Kenichi Yoshimura; Hideaki Okada; Yasuaki Sagara; Motoi Baba; Shigenori E. Nagai; Toshimi Takano, ASCO, May 2019
  • EGFR遺伝子変異陽性(exon19del/T790M)肺腺癌細胞株におけるオシメルチニブ獲得耐性機序., 山岡　利光, 第59回日本呼吸器学会学術講演会, 12 Apr. 2019, 東京
  • KRAS amplification mediates resistance to osimertinib in acquired afatinib-resistant NSCLC harboring exon 19 deletion/T790M in EGFR., YAMAOKA Toshimitsu;OHBA Motoi;KISHINO Yasunari;KUSUMOTO Sojiro;TSURUTANI Junji;OHMORI Tohru, AACR Annual Meeting 2019, 01 Apr. 2019, Atlanta
  • T790M遺伝子変異を有する肺腺癌細胞株における第3世代EGFR-TKIへの獲得耐性機序の検討, 中谷 香織;山岡 利光;大場 基;藤田 健一;荒田 悟;楠本 壮二郎;滝 伊織;亀井 大輔;鶴谷 純司;大森 亨;岩井 信市, 昭和学士会雑誌, Apr. 2019
  • EGFR遺伝子変異陽性(exon19del/T790M)肺腺癌細胞株におけるオシメルチニブ獲得耐性機序, 山岡 利光; 岸野 康成; 楠本 壮二郎; 鶴谷 純司; 相良 博典; 大森 亨, 日本呼吸器学会誌, Mar. 2019
  • 非小細胞肺癌において上皮成長因子受容体が変異活性化すると細胞外シグナル調節キナーゼを介して主要組織適合遺伝子複合体クラスIの発現が下方制御される(Mutational activation of the epidermal growth factor receptor down-regulates major histocompatibility complex class I expression via the extracellular signal-regulated kinase in non-small cell lung cancer), Watanabe Satomi;Hayashi Hidetoshi;Haratani Koji;Shimizu Shigeki;Tanizaki Junko;Sakai Kazuko;Kawakami Hisato;Yonesaka Kimio;Tsurutani Junji;Togashi Yosuke;Nishio Kazuto;Ito Akihiko;Nakagawa Kazuhiko, Cancer Science, Jan. 2019
  • Gut microbiota opens the future of cancer immunotherapy, Yoshimura Kiyoshi;Hamada Kazuyuki;Taniguchi Makoto;Hirasawa Yuya;Shida Midori;Manzaki Takashi;Ishida Hiroo;Kubota Yutaro;Tsurutani Junji;Wada Satoshi;Sambe Takehiko;Uchida Naoki;Kiuchi Yuji;Kobayashi Shinichi;Tsunoda Takuya, Proceedings for Annual Meeting of The Japanese Pharmacological Society, 2019
  • Characterization, monitoring and management of interstitial lung disease in patients with metastatic breast cancer: Analysis of data available from multiple studies of DS-8201a, a HER2-targeted antibody drug conjugate with a topoisomerase I inhibitor payload, POWELL Charles A.;CAMIDGE Ross D.;GEMMA Akihiko;KUSUMOTO Masahiko;BABA Tomohisa;KUWANO Kazuyoshi;BANKIER Alexander;KIURA Katsuyuki;TAMURA Kenji;MODI Shanu;TSURUTANI Junji;DOI Toshihiko;IWATA Hiroji;KROP Ian E.;ZHANG Lin;JASMEET Singh;SAITO Kaku;SHAHIDI Javad;YVER Antoine;TAKAHASHI Shunji, 41st Annual San Antonio Breast Cancer Symposium (SABCS 2018), 08 Dec. 2018, San Antonio
  • Trastuzumab deruxtecan (DS-8201a) in subjects with HER2-low expressing breast cancer: Updated results of a large phase 1 study, MODI Shanu;TSURUTANI Junji;TAMURA Kenji;PARK Haeseong;SAGARA Yasuaki;MURTHY Rashmi K.;IWATA Hiroji;KROP Ian E.;DOI Toshihiko;REDFERN Charles;MORENO-ASPITIA Alvaro;REDMAN Rebecca;LEE Caleb;SUGIHARA Masahiro;FUJISAKI Yoshihiko;TAKAHASHI Shunji, 41st Annual San Antonio Breast Cancer Symposium (SABCS 2018), 08 Dec. 2018, San Antonio
  • Dose justification for DS-8201a, a HER2-targeted antibody-drug conjugate, for HER2-positive breast cancer: Observed clinical data and exposure-response analyses, TAMURA Kenji;MODI Shanu;TSURUTANI Junji;TAKAHASHI Shunji;KROP Ian E.;IWATA Hiroji;WADA Russell;YIN Ophelia;GARIMELLA Tushar;SUGIHARA Masahiro;ZHANG Lin;LEE Caleb;YVER Antoine;BASELGA Jose, 41st Annual San Antonio Breast Cancer Symposium (SABCS 2018), 08 Dec. 2018, San Antonio
  • HER2陽性乳癌患者のctDNAを用いた治療効果予測に関する研究, 鶴谷 純司, 日本癌治療学会学術集会抄録集, Oct. 2018
  • MONARCH 3　未治療HR+HER2-進行乳癌におけるabemaciclib第3相試験　日本人サブ解析, 高橋 將人;戸井 雅和;徳永 えり子;山中 隆司;青儀 健二郎;鶴谷 純司;清水 千佳子;井上 晃一;森 丈治;坂口 佐知;江夏 総太郎;Di Leo Angelo;Goetz Matthew P., 日本癌治療学会学術集会抄録集, Oct. 2018
  • Updated results of phase 1 study of DS-8201a in HER2-expressing or -mutated advanced non-small cell lung cancer (NSCLC), TSURUTANI Junji;PARK Haeseong;DOI Toshihiko;MODI Shanu;TAKAHASHI Shunji;NAKAGAWA Kazuhiko;KROP E Ian;WAQAR Saiama;YOH Kiyotaka;LI Bob T;TAIRA Shinichiro;JIKOH Takahiro;SINGH Jasmeet;SUGIHARA Masahiro;PASI A Janne, IASLC 19th World Conference on Lung Cancer (WCLC 2018), 24 Sep. 2018, Toronto
  • 循環腫瘍DNAにおけるHER2ゲノム増幅とエストロゲン受容体陽性はHER2陽性転移性乳癌患者のtrastuzumab emtansine(T-DM1)に対する初期耐性を予測する(HER2 genomic amplification in circulating tumor DNA and estrogen receptor positivity predict primary resistance to trastuzumab emtansine(T-DM1) in patients with HER2-positive metastatic breast cancer), Sakai Hitomi;Tsurutani Junji;Iwasa Tsutomu;Komoike Yoshifumi;Sakai Kazuko;Nishio Kazuto;Nakagawa Kazuhiko, Breast Cancer, Sep. 2018
  • A randomized phase II trial evaluating CYP2D6 genotype-guided tamoxifen dosing in hormone receptor-positive metastatic breast cancer: TARGET-1, Toshimi Takano; Chiyo K. Imamura; Kenji Tamura; Shigehira Saji; Takeharu Yamanaka; Kan Yonemori; Masato Takahashi; Junji Tsurutani; Reiki Nishimura; Kazuhiko Sato; Akira Kitani; Naoto T. Ueno; Taisei Mushiroda; Michiaki Kubo; Yasuhiro Fujiwara; Yusuke Tanigawara, ASCO, May 2018
  • Phase II study of a combination therapy of nivolumab, bevacizumab and paclitaxel in patients with HER2-negative metastatic breast cancer as a first-line treatment (WJOG9917B, NEWBEAT trial)., Yukinori Ozaki; Koji Matsumoto; Masato Takahashi; Toru Mukohara; Manabu Futamura; Norikazu Masuda; Junji Tsurutani; Kenichi Yoshimura; Hironobu Minami; Toshimi Takano, ASCO, May 2018
  • Trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing solid tumors: Long-term results of a large phase 1 study with multiple expansion cohorts., Hiroji Iwata; Kenji Tamura; Toshihiko Doi; Junji Tsurutani; Shanu Modi; Haeseong Park; Ian E. Krop; Yasuaki Sagara; Charles H. Redfern; Rashmi Krishna Murthy; Rebecca A. Redman; Kohei Shitara; Yoshihiko Fujisaki; Masahiro Sugihara; Lin Zhang; Javad Shahidi; Antoine Yver; Shunji Takahashi, ASCO, May 2018
  • 初発骨転移症例の予後規定因子の検討, 菰池 佳史;東 千尋;田中 裕美子;濱田 未佳;新崎 亘;橋本 幸彦;北條 敏也;乾 浩己;鶴谷 純司;岩朝 勤;酒井 瞳;大和 宗久;金泉 博文;山村 順, 日本乳癌学会総会プログラム抄録集, May 2018
  • 当院における高齢者への化学療法施行の現状に関して, 岩朝 勤;鶴谷 純司;酒井 瞳;渡邊 諭美;新崎 亘;安積 達也;橋本 幸彦;菰池 佳史, 日本乳癌学会総会プログラム抄録集, May 2018
  • 乳癌化学療法による外見変化に対する医師の認識と介入の実態調査, 酒井 瞳;岩朝 勤;鶴谷 純司;菰池 佳史, 日本乳癌学会総会プログラム抄録集, May 2018
  • 進行性/再発性乳癌に対するeribulin/S-1併用療法の第II相試験(Phase II trial of Eribulin/S-1 combination therapy for advanced/recurrent breast cancer), 鶴谷 純司;岩朝 勤;水野 豊;小島 康幸;高島 勉;松並 展輝;森本 卓;山村 順;大谷 彰一郎;田辺 裕子;渡邉 諭美;加藤 了資;高野 利美;菰池 佳史;中川 和彦, 日本乳癌学会総会プログラム抄録集, May 2018
  • HER2陽性胃癌患者を対象としたDS-8201aの第1相試験の最新結果(Updated Results of Phase 1 study of DS-8201a in subjects with HER2 expressing gastric cancer), Yamaguchi Kensei;Shitara Kohei;Iwasa Satoru;Tamura Kenji;Kadowaki Shigenori;Muro Kei;Takahashi Syunji;Nonagase Yoshikane;Tsurutani Junji;Park Haeseong;Modi Shanu;Javad Shahidi;Lee Caleb;Sugihara Masahiro;Kawaguchi Yoshinori;Doi Toshihiko, 日本胃癌学会総会記事, Mar. 2018
  • 悪性リンパ腫放射線治療後、2次発癌として進行食道癌を併発した1例, 奥野 達哉;植田 勲人;武川 直樹;野長瀬 祥兼;川上 尚人;谷崎 潤子;林 秀敏;田中 薫;武田 真幸;鶴谷 純司;中川 和彦, 日本消化器病学会雑誌, Mar. 2018
  • A randomized phase II study of maintenance hormone therapy with or without capecitabine after induction therapy with bevacizumab plus paclitaxel in hormone receptor positive and HER2 negative metastatic breast cancer (KBCSG-TR1214), Miki Yamaguchi; Takahiro Nakayama; Tetsuhiro Yoshinami; Masahiko Ikeda; Mitsuhiko Iwamoto; Yoshifumi Komoike; Tsutomu Takashima; Junji Tsurutani; Katsuhide Yoshidome; Tomomi Yamada; Satoshi Morita; Norikazu Masuda, SABCS, Feb. 2018
  • Safety and efficacy results from a phase 1 study of DS-8201a in patients with HER2 expressing breast cancers, Shamu Modi; Junji Tsurutani; Shunji Takahashi; Hiroji Iwata; Haeseong Park; Charles H. Redfern; Toshihiko Doi; Bob Li; Tsutomu Iwasa; Shunichiro Taira; Masaya Hattori; Cynthia X. Ma; Jennifer M. Fisher; Yoichi Naito; Kan Yonemori; Yui Kawasaki; Kaku Saito; Takahiro Jikoh; Javad Shahidi; Caleb C. Lee; Antoine Yver; Kenji Tamura, SABCS, Feb. 2018
  • Updated results of phase 1 study of DS-8201a in subjects with HER2-expressing gastric cancer, Satoru Iwasa; Kohei Shitara; Shunji Takahashi; Haeseong Park; Shigenori Kadowaki; Shanu Modi; Yoshikane Nonagase; Kenji Tamura; Kensei Yamaguchi; Kei Muro; Junji Tsurutani; Javad Shahidi; Caleb C. Lee; Masahiro Sugihara; Yoshinori Kawaguchi; Toshihiko Doi, ASCO-GI, Feb. 2018
  • 標準治療不応のHER2発現固形癌患者に対するDS-8201aの第I相試験　中間報告, 谷口 浩也;鶴谷 純司;土井 俊彦;田村 研治;高橋 俊二;パク・ヘソン ;レッドファン・チャールズ ;リー・カレブ ;慈幸 貴洋;藤崎 良彦;イヴェル・アントワン ;岩田 広治, 日本癌治療学会学術集会抄録集, Oct. 2017
  • DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, abrogates the resistance to T-DM1 in HER2-positive gastric cancer: a preclinical study, Yoshikane Nonagase; Naoki Takegawa; Kimio Yonesaka; Kazuko Sakai; Yusuke Ogitani; Junji Tsurutani; Kazuto Nishio; Kazuhiko Nakagawa, AACR, Jul. 2017
  • 乳癌死亡17症例における、医師の予後予測と臨床経過についての検討, 菰池 佳史;松岡 梓;東 千尋;金泉 博文;濱田 未佳;新崎 亘;安積 達也;橋本 幸彦;乾 浩己;北條 敏也;大和 宗久;酒井 瞳;岩朝 勤;鶴谷 純司;金森 修一, 日本乳癌学会総会プログラム抄録集, Jul. 2017
  • 当院におけるエベロリムスの使用経験, 金泉 博文;東 千尋;濱田 未佳;新崎 亘;安積 達也;橋本 幸彦;乾 浩己;北条 敏也;大和 宗久;酒井 瞳;岩朝 勤;鶴谷 純司;菰池 佳史, 日本乳癌学会総会プログラム抄録集, Jul. 2017
  • 当院におけるエリブリン使用74例の検討, 岩朝 勤;鶴谷 純司;酒井 瞳;渡邊 諭美;新崎 亘;安積 達也;橋本 幸彦;菰池 佳史;中川 和彦, 日本乳癌学会総会プログラム抄録集, Jul. 2017
  • ER陽性乳癌に対する術前化学療法の意義について, 橋本 幸彦;東 千尋;金泉 博文;濱田 未佳;新崎 亘;安積 達也;乾 浩己;北條 敏也;大和 宗久;酒井 瞳;岩朝 勤;鶴谷 純司;金森 修一;菰池 佳史, 日本乳癌学会総会プログラム抄録集, Jul. 2017
  • 乳癌術前化学療法non-pCR症例における治療成績, 安積 達也;東 千尋;金泉 博文;久保田 倫代;濱田 未佳;藤島 成;新崎 亘;酒井 瞳;岩朝 勤;鶴谷 純司;橋本 幸彦;乾 浩己;北條 敏也;大和 宗久;金森 修一;菰池 佳史, 日本乳癌学会総会プログラム抄録集, Jul. 2017
  • T-DM1 de novo耐性HER2陽性乳癌の臨床病理学的検討, 酒井 瞳;岩朝 勤;菰池 佳史;鶴谷 純司;坂井 和子;西尾 和人;中川 和彦, 日本乳癌学会総会プログラム抄録集, Jul. 2017
  • 限局したT4B症例に対する乳房温存療法の治療成績, 東 千尋;金泉 博文;濱田 未佳;新崎 亘;安積 達也;橋本 幸彦;乾 浩己;北條 敏也;大和 宗久;菰池 佳史;酒井 瞳;岩朝 勤;鶴谷 純司, 日本乳癌学会総会プログラム抄録集, Jul. 2017
  • 大学病院における早期からの緩和ケア・地域連携の実践, 吉田 健史;松岡 弘道;小山 敦子;鶴谷 純司;中川 和彦;三瀬 博之;尾崎 公俊;前田 宗之;新田 隆, 肺癌, Jun. 2017
  • セツキシマブ耐性の大腸癌患者における血漿におけるHER2遺伝子増幅の検出, 武川 直樹;米阪 仁雄;坂井 和子;野長瀬 祥兼;植田 勲人;奥野 達哉;前西 修;川上 尚人;鶴谷 純司;田村 孝雄;中川 和彦, 日本消化器病学会雑誌, Mar. 2017
  • 免疫Checkpoint阻害剤で汎下垂体機能不全を来した悪性黒色腫の1例, 奥野 達哉;酒井 瞳;武友 保憲;岩朝 勤;田中 薫;武田 真幸;鶴谷 純司;田村 孝雄;池上 博司;中川 和彦, 日本内科学会雑誌, Feb. 2017
  • 分子標的治療薬の副作用とその対策　分子標的治療薬の副作用対策と治療ストラテジー, 鶴谷 純司, 日本癌治療学会誌, Sep. 2016
  • 患者自身の疼痛改善への期待は、疼痛予後を改善する, 松岡 弘道;牧村 ちひろ;小山 敦子;酒井 清裕;和泉 宏昌;大塚 正友;藤田 至彦;鶴谷 純司;吉田 健史;西尾 和人;中川 和彦, Palliative Care Research, Jun. 2016
  • 乳腺個別化医療を拓くバイオマーカー研究　HER2陽性乳癌個別化治療の近未来, 鶴谷 純司, 日本乳癌学会総会プログラム抄録集, Jun. 2016
  • 大学病院における早期からの緩和ケア・地域連携の実践　腫瘍内科と緩和ケアの融合の試み, 吉田 健史;和泉 宏昌;牧村 ちひろ;松岡 弘道;三瀬 博之;尾崎 公俊;前田 宗之;新田 隆;鶴谷 純司;小山 敦子;中川 和彦, Palliative Care Research, Jun. 2016
  • ALK阻害剤による治療後に小細胞肺癌・扁平上皮癌への形質転換を認めたALK融合遺伝子陽性肺癌の1例, 武川 直樹;中川 和彦;鶴谷 純司;清水 俊雄;武田 真幸;田中 薫;岩朝 勤;吉田 健史;林 秀敏;谷崎 潤子;高濱 隆幸;原谷 浩司;西田 諭美, 肺癌, Oct. 2015
  • Detection of EML4-ALK Fusion Gene by Using Nested Long-Ranged Polymerase Chain Reaction, Shinnosuke Takemoto; Hiroaki Senju; Yoichi Nakamura; Hiroshi Gyotoku; Takaya Ikeda; Hiroyuki Yamaguchi; Takeshi Kitazaki; Katsumi Nakatomi; Minoru Fukuda; Junji Tsurutani; Kazuhiro Tsukamoto; Shigeru Kohno, WCLC, Sep. 2015
  • KRAS遺伝子変異陽性肺癌の臨床的特徴, 林 秀敏;武田 真幸;金田 裕靖;鶴谷 純司;中川 和彦;寺嶋 雅人;坂井 和子;西尾 和人, 肺癌, Aug. 2015
  • 原発性乳癌における乳房MRIの副病変評価の検討, 安積 達也;久保田 倫代;濱田 未佳;新崎 亘;藤島 成;橋本 幸彦;乾 浩己;北條 敏也;大和 宗久;西田 諭美;岩朝 勤;鶴谷 純司;金森 修一;菰池 佳史, 日本乳癌学会総会プログラム抄録集, Jul. 2015
  • ホルモン陽性転移・再発乳癌に対するフルベストラントの治療成績　自験例51例の後ろ向き検討, 菰池 佳史;久保田 倫代;濱田 未佳;新崎 亘;安積 達也;橋本 幸彦;乾 浩己;北條 敏也;西田 諭美;岩朝 勉;鶴谷 純司;藤島 成;大和 宗久, 日本乳癌学会総会プログラム抄録集, Jul. 2015
  • 進行再発乳癌に対する早期レジメンとしてのEribulinの有効性・安全性の検討(SONG-BC01), 松並 展輝;阿部 元;鶴谷 純司;岩朝 勤;森島 宏隆;小田 直文;玉川 孝治;谷島 裕之;神垣 俊二;山村 順;稲治 英生;西 敏夫;中野 芳明;荻野 信夫;山崎 圭一;菰池 佳史;手塚 健志;新田 敏勝;平井 昭彦;中川 和彦;南大阪乳癌診療ネットワーク(SONG), 日本乳癌学会総会プログラム抄録集, Jul. 2015
  • 乳癌骨転移患者におけるゾレドロン酸治療に関する後ろ向きコホート研究, 田根 香織;柳江 正嗣;鶴谷 純司;谷岡 真樹;藤本 伸一郎;藤原 季美子;山添 譲;千葉 康敬;中川 和彦;菰池 佳史;高尾 信太郎, 日本乳癌学会総会プログラム抄録集, Jul. 2015
  • 当院におけるTDM-1使用状況に関して, 岩朝 勤;西田 諭美;鶴谷 純司;中川 和彦;新崎 亘;安積 達也;橋本 幸彦;菰池 佳史, 日本乳癌学会総会プログラム抄録集, Jul. 2015
  • 再発進行乳癌におけるエリブリンとTS-1療法の検討, 岩朝 勤;西田 諭美;田中 薫;工藤 慶太;吉田 健史;武田 真幸;金田 裕靖;清水 俊雄;鶴谷 純司;中川 和彦, 日本内科学会雑誌, Feb. 2015
  • 化学療法中に間質性肺炎増悪を来した肺癌患者転帰の後ろ向き検討, 高濱 隆幸;金田 裕靖;田中 薫;工藤 慶太;岩朝 勤;吉田 健史;武田 真幸;清水 俊雄;鶴谷 純司;中川 和彦, 日本内科学会雑誌, Feb. 2015
  • がん疼痛治療におけるバイオマーカー探察, 松岡 弘道;牧村 ちひろ;大塚 正友;酒井 清裕;阪本 亮;小山 敦子;西尾 和人;中川 和彦;藤田 至彦;鶴谷 純司, 日本内科学会雑誌, Feb. 2015
  • 原発不明のがん性胸膜炎に対し胸腔鏡下胸膜生検で再発乳がんの確定診断に至った症例, 宮川 知保;田中 薫;西田 諭美;野長瀬 祥兼;高濱 隆幸;吉田 健史;岩朝 勤;工藤 慶太;武田 真幸;金田 裕靖;鶴谷 純司;中川 和彦, 気管支学, Jan. 2015
  • PHASE I TRIAL OF ERIBULIN/S-1 COMBINATION THERAPY FOR ADVANCED/RECURRENT BREAST CANCER, Tsutomu Iwasa; Tsutomu Sakiyama; Junji Tsurutani; Kaoru Tanaka; Takeshi Yoshida; Yoshikane Nonagase; Yasuhito Fujisaka; Takayasu Kurata; Yoshifumi Komoike; Kazuhiko Nakagawa, ANNALS OF ONCOLOGY, Oct. 2014
  • 化学療法中に間質性肺炎増悪を来した肺癌患者転帰の後ろ向き検討, 高濱 隆幸;金田 裕靖;田中 薫;植田 勲人;西田 諭美;武川 直樹;野長瀬 祥兼;工藤 慶太;岩朝 勤;吉田 健史;武田 真幸;清水 俊雄;鶴谷 純司;田村 孝雄;中川 和彦, 肺癌, Oct. 2014
  • 日本人進行固形がん患者に対するMK-3475(抗PD-1抗体)の第I相試験, 清水 俊雄;瀬戸 貴司;平井 文彦;竹中 朋祐;鶴谷 純司;金田 裕靖;岩朝 勤;川上 尚人;野口 一夫;嶋本 隆司;中川 和彦, 肺癌, Oct. 2014
  • 高齢者乳癌に対する周術期(adjuvantおよびneoadjuvant)化学療法の忍容性と有効性についての後方視的検討, 菰池 佳史;濱田 未佳;新崎 亘;安積 達也;橋本 幸彦;鶴谷 純司;岩朝 勉;藤島 成;乾 浩己;北條 敏也;大和 宗久, 日本乳癌学会総会プログラム抄録集, Jul. 2014
  • 乳癌術後化学放射線療法中に二次性血液腫瘍を来した症例の検討, 岩朝 勤;鶴谷 純司;中川 和彦;菰池 佳史;橋本 幸彦;安積 達也;新崎 亘, 日本乳癌学会総会プログラム抄録集, Jul. 2014
  • 転移性乳癌患者を対象としたnab-Paclitaxel/S-1併用療法の臨床第I相試験, 鶴谷 純司;黒井 克昌;佐伯 俊昭;宮崎 昌樹;仁科 慎一;牧村 ちひろ;谷崎 潤子;岡本 邦男;岩朝 勤;菰池 佳史;山下 年成;有賀 智之;重川 崇;中川 和彦, 日本乳癌学会総会プログラム抄録集, Jul. 2014
  • 転移・再発乳癌に対するタキサン系薬剤とTS-1のランダム化比較試験(SELECT-BC), 相良 吉昭;高島 勉;原 文堅;渡辺 隆紀;穂積 康夫;鶴谷 純司;井本 滋;西村 令喜;大橋 靖雄;向井 博文, 日本乳癌学会総会プログラム抄録集, Jul. 2014
  • 転移・再発乳癌に対するタキサン系薬剤とTS-1の無作為化比較第3相試験(SELECT-BC), 穂積 康夫;高島 勉;原 文堅;相良 吉昭;渡辺 隆紀;鶴谷 純司;井本 滋;西村 令喜;高野 利実;朴 英進;遠山 竜也;斎藤 毅;松原 伸晃;大橋 靖雄;向井 博文, 日本癌治療学会誌, Jun. 2014
  • PHASE I AND PHARMACOKINETIC STUDY OF AMATUXIMAB, A NOVEL CHIMERIC ANTIBODY TO MESOTHELIN, IN PATIENTS WITH ADVANCED SOLID TUMORS, Takayasu Kurata; Yasuhito Fujisaka; Kaoru Tanaka; Toshihiro Kudo; Kunio Okamoto; Junji Tsurutani; Hiroyasu Kaneda; Isamu Okamoto; Masayuki Namiki; Chifumi Kitamura; Kazuhiko Nakagawa, WCLC, Nov. 2013
  • Phase I dose finding study of AZD8931, an inhibitor of EGFR, HER2, and HER3 signaling, alone or in combination with paclitaxel in Japanese patients., Yasuhito Fujisaka; Takayasu Kurata; Junji Tsurutani; Wataru Okamoto; Hidetoshi Hayashi; Hisato Kawakami; Eisei Shin; Nobuya Hayashi; Kazuhiko Nakagawa, ASCO, May 2013
  • Overexpression of FOXQ1 is important factor in tumorigenicity and tumor growth, Hiroyasu Kaneda; Tokuzo Arao; Kaoru Tanaka; Daisuke Tamura; Keiichi Aomatsu; Kanae Kudo; Kazuko Sakai; Marco Antonio De Velasco; Kazuko Matsumoto; Fujita Yoshihiko; Yasuhide Yamada; Junji Tsurutani; Isamu Okamoto; Kazuhiko Nakagawa; Kazuto Nishio; Tomoyuki Nagai; Kazuyuki Furuta, CANCER RESEARCH, Apr. 2010
  • Phase I study of sunitinib (SU) in combination with pemetrexed (Pem) in patients (pts) with advanced solid tumors (ST), Kazuhiko Nakagawa; Isamu Okamoto; Toshio Shimizu; Masaki Miyazaki; Junji Tsurutani; Yasuko Ichikawa; Masaaki Terashima; Masayuki Takeda; Soichi Fumita; Tsukasa Kiriyama, JOURNAL OF THORACIC ONCOLOGY, Sep. 2009
  • Autoimmunity to heat shock protein 40 in ulcerative colitis (vol 32, pg 141, 2004), S Sato; M Oka; Y Noguchi; H Soda; J Tsurutani; Y Nakamura; T Kitazaki; Y Mizuta; F Takeshima; K Murase; Murata, I; K Ohtsuka; S Kohno, JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, May 2004
  • Erratum: Autoimmunity to heat shock protein 40 in ulcerative colitis (The Journal of International Medical Research (2004) vol. 32 (141-148)), S. Sato; M. Oka; Y. Noguchi; H. Soda; J. Tsurutani; Y. Nakamura; T. Kitazaki; Y. Mizuta; F. Takeshima; K. Murase; I. Murata; K. Ohtsuka; S. Kohno, Journal of International Medical Research, May 2004
  • 【肺癌に対する新たな分子標的治療　21世紀はこう変わる】肺癌治療戦略の新たな展開　非小細胞肺癌の標準的化学療法, 岡 三喜男;中村 洋一;鶴谷 純司, 内科, Nov. 2001
  • 非小細胞肺癌株PC14におけるCYP3A4の発現誘導, 築山 正嗣;中川 和彦;小宮 武文;吉田 誠;鶴谷 純司;山本 信之;植島 久雄;秋山 慶太;田村 研治;倉田 宝保, 日本癌学会総会記事, Sep. 2001
  • cDNAマクロアレイを用いた新規抗癌剤Amrubicinの非小細胞肺癌細胞株PC-14に及ぼす遺伝子発現変化の解析, 鶴谷 純司;小宮 武文;田村 研治;築山 正嗣;秋山 慶太;浅井 暁;植島 久雄;洪 泰浩;芥川 茂;小泉 史明, 日本癌学会総会記事, Sep. 2001
  • 肺癌細胞におけるSulfonylurea receptor 1,2の発現誘導, 秋山 慶太;田村 研治;鶴谷 純司;築山 正嗣;浅井 暁;小宮 武文;倉田 宝保;植島 久雄;山本 信之;中川 和彦, 日本癌学会総会記事, Sep. 2001
  • 非小細胞肺癌株におけるCYP3A4の発現誘導, 築山 正嗣;小宮 武文;山本 信之;吉田 誠;秋山 慶太;鶴谷 純司;植島 久雄;中川 和彦;福岡 正博, 肺癌, Apr. 2001
  • 肺癌におけるβ-tubulin遺伝子の解析, 鶴谷 純司;小宮 武文;築山 正嗣;植島 久雄;山本 信之;中川 和彦;福岡 正博, 近畿大学医学雑誌, Apr. 2001
  • 固形癌に対するタキソール,ゲムシタビン,ビノレルビン併用化学療法の臨床第I相試験, 児玉 圭司;山本 信之;秋山 慶太;築山 正嗣;鶴谷 純司;坂井 幸子;浅井 曉;家田 泰浩;吉田 誠;森山 あづさ, 日本呼吸器学会雑誌, Mar. 2001
  • 各種抗癌剤による薬剤耐性遺伝子発現誘導, 築山 正嗣;吉田 誠;中川 和彦;小宮 武文;畑下 恵理奈;森山 あづさ;鶴谷 純司;植島 久雄;山本 信之;西尾 和人, 日本呼吸器学会雑誌, Mar. 2001
  • 新規抗がん剤ritterazine B, 小宮 武文;鶴谷 純司;吉田 誠;植島 久雄;山本 信之;福岡 正博;中川 和彦, 肺癌, Oct. 2000
  • 再発腎がんに対しinterleukin-2が奏効した1例, 児玉 圭司;秋山 慶太;築山 正嗣;家田 泰弘;坂井 幸子;吉田 誠;鶴谷 純司;浅井 暁;森山 あづさ;小宮 武文, 肺癌, Oct. 2000
  • パクリタキセル(タキソール)がイリノテカンの薬物動態に及ぼす影響, 浅井 暁;山本 信之;小宮 武文;森山 あづさ;児玉 圭司;鶴谷 純司;吉田 誠;築山 正嗣;秋山 慶太;中川 和彦, 日本癌学会総会記事, Sep. 2000
  • 固形癌に対するNon-Platinum Tripletの臨床第I相試験, 児玉 圭司;山本 信之;秋山 慶太;築山 正嗣;鶴谷 純司;浅井 暁;森山 あづさ;小宮 武文;植島 久雄;中川 和彦, 日本癌治療学会誌, Sep. 2000
  • 局所進行型非小細胞肺がんに対するweekly Taxotere(TXT)+Cisplatin(CDDP)と胸部放射線の同時併用療法の第I相試験, 平島 智徳;山本 信之;中川 和彦;野上 壽二;植島 久雄;小宮 武文;森山 あづさ;浅井 暁;児玉 圭司;鶴谷 純司, 日本癌治療学会誌, Sep. 2000
  • 新規抗がん剤ritterazineB, 小宮 武文;鶴谷 純司;吉田 誠;山本 信之;植島 久雄;福岡 正博;伏谷 伸宏;中川 和彦, 日本癌学会総会記事, Sep. 2000
  • 各種抗癌剤による薬剤耐性遺伝子発現誘導, 吉田 誠;中川 和彦;小宮 武文;畑下 恵理奈;森山 あづさ;鶴谷 純司;植島 久雄;山本 信之;西尾 和人;福岡 正博, 肺癌, Sep. 2000
  • 固形癌に対するタキソール,ゲムシタビン,ビノレルビン併用化学療法の臨床第I相試験, 児玉 圭司;山本 信之;秋山 慶太;築山 正嗣;鶴谷 純司;坂井 幸子;浅井 曉;家田 泰浩;吉田 誠;森山 あづさ, 肺癌, Sep. 2000
  • ヒト小細胞肺癌株におけるβtubulin遺伝子異常, 鶴谷 純司;小宮 武文;植島 久雄;山本 信之;中川 和彦;福岡 正博;平島 智徳, 日本癌学会総会記事, Sep. 2000
  • 再発ないし前治療無効小細胞肺癌に対する塩酸イリノテカンとドキソルビシン併用の第II相試験, 植島 久雄;根来 俊一;鶴谷 純司;児玉 圭司;浅井 暁;森山 あづさ;小宮 武文;山本 信之;中川 和彦;武田 晃司, 肺癌, Sep. 2000
  • 小細胞肺癌患者における腫瘍マーカー値と治療効果との関係, 築山 正嗣;山本 信之;山上 富美子;秋山 慶太;鶴谷 純司;児玉 圭司;浅井 暁;森山 あづさ;小宮 武文;植島 久雄, 肺癌, Sep. 2000
  • 肺小細胞癌における腫瘍マーカーPro-GRP,NSEの有用性, 山上 富美子;植島 久雄;坂井 幸子;鶴谷 純司;児玉 圭司;家田 泰浩;吉田 誠;飯田 あづさ;浅井 暁;小宮 武文, 肺癌, Apr. 2000
  • 非小細胞肺癌に対するweekly CDDP+docetaxel concurrent thoracic radiotherapyの第I/II相試験, 児玉 圭司;山本 信之;中川 和彦;植島 久雄;小宮 武文;浅井 暁;飯田 あずさ;家田 泰浩;鶴谷 純司;坂井 幸子, 日本呼吸器学会雑誌, Mar. 2000
  • 肺癌に伴い治療に苦慮した気胸の一例, 清水 俊雄;浅井 暁;児玉 圭司;鶴谷 純司;山本 信之;廣畑 健;原 聡;福岡 正博, 気胸, Dec. 1999
  • 薬剤血中濃度が高値を示した4症例, 木元 克治;松永 満成;富永 正樹;鶴谷 純司, 武雄杵島臨床医学誌, Apr. 1999
  • 気管支鏡治療が成功した気管粘膜リンパ組織リンパ腫の1例, Tsurutani Junji;Kinoshita Akitoshi;Kaida Hideyuki;Fujii Hideharu;Narasaki Fumihiko;Fukuda Minoru;Oka Mikio;Kohno Shigeru, Internal Medicine, Mar. 1999
  • 気管支動脈塞栓術が著効した気管分岐部血管病変の1例, 西岡 克章;木下 明敏;貝田 英之;鶴谷 純司;佐伯 幸子;神崎 修一;森 雅一;河野 茂, 国立長崎中央病院医学雑誌, Mar. 1999
  • 原発性肺B細胞リンパ腫の診断のための気管支肺胞洗浄の評価, Nakano Reiji;Oka Mikio;Watanabe Masami;Soda Hiroshi;Terashi Kenji;Fukuda Minoru;Narasaki Fumihiko;Kawabata Shigeru;Tsurutani Junji;Nagashima Seiji;Tsukamoto Kazuhiro;Noguchi Yuji;Kohno Shigeru, Acta Medica Nagasakiensia, Dec. 1998
  • 気管・気管支MALTリンパ腫の2例, 鶴谷 純司, 気管支学会, Jun. 1997
  • 23. エタノール局所注入が秦効した食道癌気管浸潤による気道閉塞の 1 例(第 20 回日本気管支学会九州支部総会), 木下 明敏; 鶴谷 純司; 古川 正人; 辻 博治; 仲地 厚; 天本 祐平; 荒木 潤; 岡三 喜男; 河野 茂, 気管支学, 1997

Books etc

  • 新臨床腫瘍学（改訂第７版）, 3）HER2阻害薬　a.　小分子化合物, 日本臨床腫瘍学会, 南江堂, Feb. 2024
  • 図解ですっきり！抗がん薬の薬理作用, 南博信、寺田智祐、鶴谷純司ほか, 南江堂, Jul. 2023
  • 乳癌診療 stage of the art　科学に基づく最新診療, 戸井雅和、中村清吾、鶴谷純司ほか, 医歯薬出版株式会社, Sep. 2022
  • 乳腺腫瘍学（第４版）, 日本乳癌学会, 金原出版株式会社, Jun. 2022
  • 遺族ケアガイドライン 2022年版, 日本サイコオンコロジー学会、日本がんサポーティブケア学会, 金原出版, Jun. 2022
  • がん免疫ペディア, 吉村清、鶴谷純司ほか, 羊土社, Mar. 2022
  • 遺伝性乳癌卵巣癌（HBOC）診療ガイドライン2021年版, 日本遺伝性乳癌卵巣癌総合診療制度機構, 金原出版株式会社, Jul. 2021
  • 乳がん薬物療法 副作用マネジメント プロのコツ 改訂第2版, 増田慎三、鶴谷純司ほか, メジカルビュー社, Jun. 2021
  • 新臨床腫瘍学（第６版）, HER2阻害薬, 日本臨床腫瘍学会, 南江堂, May 2021
  • 乳腺腫瘍学, 日本乳癌学会, 金原出版株式会社, Apr. 2020
  • 新臨床腫瘍学（第５版）, HER2阻害薬, 日本臨床腫瘍学会, 南江堂, Jul. 2018
  • 乳がん薬物療法副作用マネジメント, 増田慎三、鶴谷純司ほか, メジカルビュー社, Sep. 2017
  • Expert choice乳がんレジメン, 渡辺, 亨, 安藤, 正志, 勝俣, 範之, 清水, 千佳子, 鶴谷, 純司, 原, 文堅, 先端医学社, Dec. 2015
  • 入門腫瘍内科学（改訂第２版）, 日本臨床腫瘍学会, 篠原出版新社, Mar. 2015

Research Projects

  • アベマシクリブを服用した転移性乳癌患者を対象に使用実態及び有効性を評価する国際共同観察研究（ABCR2）, 鶴谷純司　研究統括, IQVIA, Eli Lilly, From 202301, To 202403, Industry academia cooperation
  • 難治性腫瘍形成における葉酸受容体発現の機序と役割解明　基盤研究（C）, 鶴谷純司　研究代表者, 日本学術振興会, From 202204, To 202503, Competitive research funding
  • CDK4/6阻害剤気治療後の腫瘍組織を用いてFoundation one検査を施行した症例/FGFR mutation/amlificationを認めた症例を対象としたRNA-seqによる網羅的遺伝子解析と、EMT-score/IO subtype同定による、ホルモン療法耐性、化学療法効果の予測性の検証試験, 鶴谷純司　研究統括者, エーザイ株式会社, From 202004, To 202305, Industry academia cooperation
  • Abemaciclib for metastatic breast cancer (MBC) Chart Review, Junji Tsurutani, FUNDACIÓ PRIVADA PER A LA RECERCA I LA DOCÈNCIA SANT JOAN DE DÉU, From 202004, To 202103, Industry academia cooperation
  • 乳がん患者に対する化学療法後のしびれ症状改善を目指すハンドセラピー技術の確立　基盤研究（C）, 鶴谷純司　研究分担者, 日本学術振興会, From 201904, To 202203, Competitive research funding
  • Anti-tumor effect of MORAb-202 (anti-FRA ADC) in NSCLC and non-TNBC cell lines, Junji Tsurutani , PI, Morphotek Inc., From 201904, To 202103, Industry academia cooperation
  • cell free DNAを用いたHER2陽性進行・再発乳がんにおけるトラスツズマブ、 ペルツズマブ、化学療法の効果予測モデルに関する研究, 鶴谷純司　研究代表者, 日本癌治療学会, From 201604, To 201703, Competitive research funding
  • 未治療原発不明癌に対する次世代シークエンスを用いた原発巣推定に基づく治療効果の意義を問う第Ⅱ相試験, 鶴谷純司　研究分担者, 日本医療研究開発機構研究費 革新的がん医療実用化研究事業, From 201504, To 201703, Competitive research funding
  • がん疼痛へのオピオイド使用に対するバイオマーカーを用いたランダム化比較試験, 鶴谷純司　研究分担者, 日本医療研究開発機構研究費 革新的がん医療実用化研究事業, From 201504, To 201703, Competitive research funding
  • がん疼痛へのオピオイド使用に対するバイオマーカーを用いたランダム化比較試験, 鶴谷純司　研究分担者, 厚生労働省 革新的がん医療実用化研究事業, From 201404, To 201503, Competitive research funding
  • 進行非小細胞肺癌を対象としたエルロチニブとYM155の分子標的治療薬併用第I相試験, 鶴谷純司　研究分担者, 厚生労働省 難病・がん等の疾患分野の医療の実用化研究事業, From 201204, To 201403, Competitive research funding

MISC

  • 【教育】文部科学省がん専門医療人材養成事業　８大学関東がんプロのeラーニング作成, 鶴谷純司, Feb. 2024
  • 【教育】先端がん治療研究セミナー（文科省がんプロ共催、昭和大学学士会後援） 　　演題：臨床研究法を取り巻く環境と展望 　　, 講師：厚生労働省医政局研究開発政策課治験推進室　片岡智子, Nov. 2023
  • 【教育】文部科学省がん専門医療人材養成事業　４大学連携多職種ワークショップ, ファシリテーター：鶴谷純司, Aug. 2023
  • 【教育】第二延山小学校のがん教育授業の外部講師, 鶴谷純司, May 2023
  • 乳がんに対する薬物療法の最前線, 鶴谷　純司, 昭和学士会雑誌, 81(3):162 - 165, Aug. 2021
  • 【乳癌における免疫チェックポイント阻害薬の新たな展開】乳癌周術期免疫チェックポイント阻害薬, 鶴谷 純司, 乳癌の臨床, 36(3):181, Jul. 2021
  • 【先端ゲノム医療とゲノム診療】各臓器がんのゲノム診療の現状　乳がんとゲノム医療, 吉田 玲子;鶴谷 純司, 腫瘍内科, 27(1):66, Jan. 2021
  • Evaluation of the benefits of administering hand therapy to patients with chemotherapy-induced peripheral neuropathy, 佐々木　晶子;池田　明子;角田　ゆう子;澤田　晃暢;鶴谷　純司;辰尾　秋斗;木内　祐二;中村　清吾, 癌と化学療法, 47(5):783 - 788, May 2020
  • [Evaluation of the Benefits of Administering Hand Therapy to Patients with Chemotherapy-Induced Peripheral Neuropathy]., Sasaki Akiko;Ikeda Akiko;Tsunoda Yuko;Sawada Terumasa;Tsurutani Junji;Tatsuo Tokito;Kiuchi Yuji;Nakamura Seigo, Gan to kagaku ryoho. Cancer & chemotherapy, 47(5), 2020
  • Olfactomedin-4の発現は膵臓癌における抗癌剤耐性と予後不良に関与する, 大熊 遼太朗;久保田 祐郎;濱田 和幸;石田 博雄;平澤 優弥;有泉 弘嗣;佐藤 悦子;鶴谷 純司;吉村 清;青木 武士;村上 雅彦;野呂瀬 朋子;大池 信之;瀧本 雅文;泉崎 雅彦;角田 卓也;和田 聡, 昭和学士会雑誌, 79(3):416, Jun. 2019
  • T790M遺伝子変異を有する肺腺癌細胞株における第3世代EGFR-TKIへの獲得耐性機序の検討, 中谷 香織; 山岡 利光; 大場 基; 藤田 健一; 荒田 悟; 楠本 壮二郎; 滝 伊織; 亀井 大輔; 鶴谷 純司; 大森 亨; 岩井 信市, 昭和学士会雑誌, 79(2):249 - 249, Apr. 2019
  • 【新薬展望2019】(第II部)注目の新薬　抗悪性腫瘍剤(CDK4/6阻害剤)　一般名:パルボシクリブ　イブランスカプセル25mg,同125mg, 増田 紘子;鶴谷 純司, 医薬ジャーナル, 55(増刊):231, Jan. 2019
  • 【乳がん・婦人科がん】HER2陽性乳がんの治療戦略　標準治療と臨床開発のトピック(術前化学療法～転移性乳がんまで), 岩朝 勤;鶴谷 純司, 腫瘍内科, 22(3):260, Sep. 2018
  • 誌上ディベート　術後アロマターゼ阻害薬は5年か、5年以上か　「5年以上とすべき」とする立場から, 酒井 瞳;鶴谷 純司, Cancer Board of the Breast, 4(2):107, Aug. 2018
  • heregulin発現HER2陽性乳癌・胃癌における抗HER2薬ラパチニブ、トラスツズマブ、T-DM1の感受性に関する研究, 野長瀬 祥兼;米阪 仁雄;川上 尚人;渡邉 諭美;原谷 浩司;高濱 隆幸;武川 直樹;植田 勲人;谷崎 潤子;林 秀俊;吉田 健史;武田 真幸;千葉 康敬;中川 和彦;鶴谷 純司, 近畿大学医学雑誌, 42(3-4):25A, Dec. 2017
  • 【乳がんに対する新しい診断法や治療法】ホルモン受容体陽性進行乳がんに対するCDK4/6阻害薬, 酒井 瞳;鶴谷 純司, 腫瘍内科, 20(3):194, Sep. 2017
  • 多遺伝子アッセイを用いた乳がん化学療法省略の可能性　TAILORx試験およびMINDACT試験の結果から, 酒井 瞳;鶴谷 純司, がん分子標的治療, 14(4):511, Jan. 2017
  • 【乳がんに対する新しい診断技術と治療戦略】転移・再発HER2陽性乳がんの標準治療, 岩朝 勤;鶴谷 純司, 腫瘍内科, 18(3):220, Sep. 2016
  • 【早期乳がんおよび進行乳がんに対する新しい標準治療の開発】乳がんの分子標的薬の新戦略, 岩朝 勤;鶴谷 純司, 腫瘍内科, 15(5):450, May 2015
  • 【HER2による乳がん治療戦略の方向性】次世代シーケンス解析とHER2陽性乳がんのゲノム異常, 鶴谷 純司, 腫瘍内科, 14(3):224, Sep. 2014
  • 【乳がん薬物療法2014】閉経前ホルモン受容体陽性乳がんに対する術後内分泌療法, 鶴谷 純司, Mebio, 31(7):8, Jul. 2014
  • 【注目すべき新標的と期待される次世代抗悪性腫瘍薬】HSPを標的としたがん治療の可能性, 鶴谷 純司, 腫瘍内科, 13(6):786, Jun. 2014
  • 研修医からの質問Q&A　これまで経験のない再発形式を認めた乳がん症例への化学療法を検討していますが?, 鶴谷 純司, 臨床腫瘍プラクティス, 10(2):275, May 2014
  • Discussion about Biomilar development: Filgrastim BS injection and its applications in clinical practice., Saeki T; Tokuda Y; Takigawa N; Tsurutani J, Gan To Kagaku Ryoho, Oct. 2013
  • 乳がんに対する化学療法の著効例, 寺嶋 応顕; 鶴谷 純司; 中川 和彦, 臨床腫瘍プラクティス, 6(4):465 - 468, Nov. 2010

Copyright © MEDIA FUSION Co.,Ltd. All rights reserved.